JPH0780778B2 - Antidiabetic agent - Google Patents
Antidiabetic agentInfo
- Publication number
- JPH0780778B2 JPH0780778B2 JP62204905A JP20490587A JPH0780778B2 JP H0780778 B2 JPH0780778 B2 JP H0780778B2 JP 62204905 A JP62204905 A JP 62204905A JP 20490587 A JP20490587 A JP 20490587A JP H0780778 B2 JPH0780778 B2 JP H0780778B2
- Authority
- JP
- Japan
- Prior art keywords
- earthworm
- water
- acid
- live
- earthworms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003472 antidiabetic agent Substances 0.000 title claims description 8
- 229940125708 antidiabetic agent Drugs 0.000 title claims description 5
- 241000361919 Metaphire sieboldi Species 0.000 claims description 183
- 239000000843 powder Substances 0.000 claims description 134
- 241001233061 earthworms Species 0.000 claims description 70
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 206010012601 diabetes mellitus Diseases 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 239000000725 suspension Substances 0.000 claims description 23
- 239000007864 aqueous solution Substances 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- -1 organic acid sodium salt Chemical class 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 18
- 239000013505 freshwater Substances 0.000 claims description 17
- 238000001291 vacuum drying Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 239000003125 aqueous solvent Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 150000007524 organic acids Chemical class 0.000 claims description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 7
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000001630 malic acid Substances 0.000 claims description 7
- 235000011090 malic acid Nutrition 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 235000011054 acetic acid Nutrition 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 238000001238 wet grinding Methods 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 239000002699 waste material Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 40
- 239000008280 blood Substances 0.000 description 40
- 238000004519 manufacturing process Methods 0.000 description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 24
- 239000002775 capsule Substances 0.000 description 22
- 235000000346 sugar Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 235000019359 magnesium stearate Nutrition 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 9
- 235000005822 corn Nutrition 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 239000007902 hard capsule Substances 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000011812 mixed powder Substances 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000002550 fecal effect Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 6
- 230000003480 fibrinolytic effect Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940098465 tincture Drugs 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 5
- 238000011047 acute toxicity test Methods 0.000 description 5
- 235000021152 breakfast Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 235000011007 phosphoric acid Nutrition 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000243684 Lumbricus Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000021158 dinner Nutrition 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 241001495098 Lumbricus rubellus Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229910052814 silicon oxide Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000237636 Pheretima Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- CATSNJVOTSVZJV-UHFFFAOYSA-N heptan-2-one Chemical compound CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N isobutyl acetate Chemical compound CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PGEVTVXEERFABN-UHFFFAOYSA-N 1,1-dichloropentane Chemical compound CCCCC(Cl)Cl PGEVTVXEERFABN-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LBKMJZAKWQTTHC-UHFFFAOYSA-N 4-methyldioxolane Chemical compound CC1COOC1 LBKMJZAKWQTTHC-UHFFFAOYSA-N 0.000 description 1
- CPIVYSAVIPTCCX-UHFFFAOYSA-N 4-methylpentan-2-yl acetate Chemical compound CC(C)CC(C)OC(C)=O CPIVYSAVIPTCCX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241001262938 Allolobophora Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000357261 Dendrobaena octaedra Species 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 241000985366 Drawida hattamimizu Species 0.000 description 1
- 241000243686 Eisenia fetida Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001290772 Limnodrilus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 241000881741 Pontodrilus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000243653 Tubifex Species 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- DCKVNWZUADLDEH-RXMQYKEDSA-N [(2r)-butan-2-yl] acetate Chemical compound CC[C@@H](C)OC(C)=O DCKVNWZUADLDEH-RXMQYKEDSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001239 fibrinogenlytic effect Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- RXTNIJMLAQNTEG-UHFFFAOYSA-N methylamyl acetate Natural products CCCCC(C)OC(C)=O RXTNIJMLAQNTEG-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 産業上の利用分野: 本発明は糖尿病の治療剤に関する。さらに詳しく述べれ
ば、すぐれた血中糖量(以下血糖と称する。)低下活性
と安全性をもつミミズの乾燥粉末及び/又はミミズの抽
出部の糖尿病治療剤に関する。その内、特に新規で且つ
進歩性のある改良製法によるミミズ乾燥粉末さらに、こ
れの抽出物を有効成分とする糖尿病の治療・予防剤に関
する。TECHNICAL FIELD The present invention relates to a therapeutic agent for diabetes. More specifically, the present invention relates to a dry powder of earthworm and / or a therapeutic agent for diabetes in an earthworm extract portion, which has an excellent activity of lowering blood sugar (hereinafter referred to as blood sugar) and safety. Among them, the present invention relates to an earthworm dry powder prepared by an improved manufacturing method which is novel and innovative, and further relates to a therapeutic / preventive agent for diabetes which contains an extract thereof as an active ingredient.
従来の技術: ミミズは太古の昔より主として東洋諸国において蚯蚓、
地竜と称し、薬として用いられてきた。従来の文献に報
告されているミミズの薬理・薬効作用を下記に示す。Prior Art: Earthworms have been the silkworm from the ancient times, mainly in the Eastern countries,
It is called a earth dragon and has been used as a medicine. The pharmacological and pharmacological actions of earthworms reported in conventional literature are shown below.
「みみずと人生」大淵眞龍著1947年(昭和22年)10
月30日、牧書房発行、第223〜226頁及び「復刻みみず」
畑井新喜司著1980年4月30日、株式会社サイエンテイス
ト社発行、第160〜163頁に、ミミズが膀胱内結石の縮小
作用剤及び体外への排出作用剤、黄疽の治療剤・分娩剤
・強壮剤、毛生薬、強精剤及び解熱剤の薬理作用を有
し、一方、ミミズ毒として、一つは神経系統を侵し、他
は赤血球の破壌即ち、溶血作用を有することを報告して
いる。"Water and life" by Shinryu Obuchi 1947 (Showa 22) 10
Published by Maki Shobo, pages 223-226 and "Reprinted Water"
Shinji Hatai, April 30, 1980, published by Scientist Co., Ltd., pp. 160-163, worms are agents for reducing bladder stones and for discharging them to the outside of the body, therapeutic agents for jaundice and delivery. It has been reported that it has the pharmacological action of drugs, tonics, hair crude drugs, strong sperm agents and antipyretics, while as an earthworm poison, one has a nervous system damage, the other has a hemolytic action of red blood cells. .
「中華人民共和国葯典」中華人民共和国衛生部葯典
委員会編、1977年版、一部第197〜198頁には、次のこと
が記載されている。慣習的に地竜製品には2種類があ
る。その一つの広地竜(Lumbricus Kwangtungesis)
は、腹部を裂いて内臓と泥砂を洗い流し、天日、日陰又
は低温で乾燥させたものである。他の土地竜(Lumbricu
s Nativus)は草木灰の中に入れて殺したのち、灰をと
り去って天日、日陰又は低温で乾燥したもので、ミミズ
体内には泥土がつまっている。これらの2種の地竜は解
熱剤、ひきつけ治療剤、血行促進剤、半身不随治療剤、
関節鎮痛剤、排尿剤、気管支喘息剤及び高血圧症剤とし
て4.5〜9g/日使用すると報告している。"People's Republic of China Anthology" The People's Republic of China Ministry of Health Anthology Committee edition, 1977 edition, some pages 197-198, the following is described. By convention, there are two types of Chiryu products. One of them is Lumbricus Kwangtungesis
Is one in which the abdomen is torn to wash off the internal organs and mud and dried in the sun, shade or low temperature. Other Land Dragon (Lumbricu
s Nativus) is killed by putting it in plant ash and then removing the ash and drying it in the sun, in the shade or at low temperature, and earthworms are clogged with mud. These two types of earth dragons are antipyretic, attracting remedy, blood circulation promoter, hemiplegic treatment,
It is reported to be used as a joint pain reliever, a urinary drug, a bronchial asthma drug and a hypertensive drug at 4.5 to 9 g / day.
「わたしたちの漢方薬シリーズ3、地竜・烏賊骨/
中国の科学研究」1978年10月30日、松浦薬業株式会社発
行、第7頁には地竜チンキ(地竜のエチルアルコール抽
出物)には降圧作用のあることを報告している。"Our Chinese medicine series 3, earth dragons / crow bones /
"Scientific research in China" October 30, 1978, published by Matsuura Pharmaceutical Co., Ltd., page 7 reports that Jilong tincture (ethyl alcohol extract of Jilong) has antihypertensive effect.
「天然薬物事典」奥田拓男編、昭和61年4月15日、
廣川書店発行、第215頁には、地竜が下熱剤、鎮痛剤、
利尿剤及び解毒剤に利用されていることを報告してい
る。"Natural Drug Encyclopedia," edited by Takuo Okuda, April 15, 1986,
Published by Hirokawa Shoten, page 215, Jiryu was a hypothermic agent, painkiller,
It has been reported to be used as a diuretic and antidote.
田中護〔北海道医学雑誌第24巻、第18〜24頁(1949
年)〕は、蚯蚓(乾燥細片物から泥土に除いたもの)は
煮沸水で抽出し、この抽出液の濃縮液にエチルアルコー
ルを添加して得た沈澱物質(Lumbrofebrin)をリンゲル
氏液に溶解し、この液を麻酔下の猫に静脈注射すると急
激な血圧降下をきたし、かつショックに比例して血液凝
固の促進が認められたと報告している。Mamoru Tanaka [Hokkaido Medical Magazine Vol. 24, pp. 18-24 (1949
)], Silkworms (dried pieces removed from mud) were extracted with boiling water, and the precipitated substance (Lumbrofebrin) obtained by adding ethyl alcohol to the concentrated solution of this extract was added to Ringer's solution. It is reported that when this solution was dissolved and this solution was intravenously injected into an anesthetized cat, a rapid decrease in blood pressure was observed, and accelerated blood coagulation was observed in proportion to shock.
居川賢二郎〔山口医学第9巻、第571〜第576頁(19
60年)〕は地竜の生理食塩水の抽出液、地竜のエチルア
ルコール又はアセトン抽出乾燥物を生理食塩水に溶解し
た液を成熟家兎に静脈注射して血圧の降下を認めた。Kenjiro Igawa [Yamaguchi Medical Vol. 9, 571-576 (19
(60 years)], the physiological saline extract of Chiryu, the solution of the extract of Chiryu's ethyl alcohol or acetone in physiological saline was intravenously injected into a mature rabbit, and a decrease in blood pressure was observed.
「中葯大辞典」下巻江蘇新医学院編、1980年、上海
科学技術出版社発行、第2112頁には広地竜チンキ、蚯蚓
乾燥粉末懸濁液、蚯蚓の熱水浸せき液、蚯蚓の煎じ液等
を麻酔下の犬・大きなネズミ、猫又は慢性腎性高血圧の
ハツカネズミに投薬したら緩慢にして持続的な血圧降下
作用がみられた。麻酔下の犬又は猫に地竜エキスを静脈
注射したところ、血圧降下作用が急速に現された。ただ
し、経口投薬したり、臨床への応用では効果がなかった
と報告している。更に同誌の第2114頁には、濃度40%の
地竜チンキ(地竜40gを60度のエチルコール100mlに浸せ
き)を毎回10ml、一日に3度〔すなわち地竜12g/日に相
当する。(本発明者が換算)〕服用する。チンキを飲め
ない者は、純粋な地竜粉末に水を加えて丸薬(少量の賦
形剤を加える)をつくり、毎回3〜4g、一日に3度〔地
竜9〜12g/日に相当(本発明者が換算)〕服用し、30〜
60日間服用続けると本態性高血圧症に効果がある。又、
地竜B1液(HgCl2を用いてヒポキサンチンを除き、イオ
ン交換樹脂を用いて血圧降下成分を分離し、とり出した
もの)を毎回2ml(生薬の地竜8gを含む)を一日に3度
〔地竜24g/日に相当(本発明者が換算)〕服用すると本
態性高血圧症に効果があったと報告している。`` Chuan Andai Dictionary '' edited by Shimaki Jiangsu New Medical School, 1980, published by Shanghai Science and Technology Publishing Co., Ltd., page 2112: Hirochi Ryu tincture, dried silkworm powder powder suspension, hot water immersion liquid of silkworm, decoction of silkworm, etc. Was administered to anesthetized dogs, large mice, cats or mice with chronic renal hypertension, a slowing and persistent hypotensive effect was observed. When the dog or cat under anesthesia was intravenously injected with Chiryu extract, the hypotensive effect was rapidly exhibited. However, it was reported that it was not effective in oral administration and clinical application. Furthermore, on page 2114 of the same magazine, 10 ml of a 40% concentration earth dragon tincture (40 gram of earth dragon is dipped in 100 ml of ethyl call of 60 degrees) each time, 3 times a day [that is equivalent to 12 grams of earth dragon / day. (Converted by the inventor)] Take. For those who cannot drink tincture, add water to pure earth dragon powder to make pills (add a small amount of excipients), 3 to 4 g each time, 3 times a day [equivalent to earth dragon 9 to 12 g / day. (Converted by the present inventor)]
Continued use for 60 days is effective for essential hypertension. or,
Chiryu B 1 liquid (HgCl 2 is used to remove hypoxanthine, ion-exchange resin is used to separate the blood pressure-lowering components, and the extracted) 2 ml each time (including Chiryu 8 g of herbal medicine) It has been reported that when taken three times [equivalent to 24 g / day of earth dragon (converted by the present inventor)], it was effective for essential hypertension.
従来の慣習的なミミズの乾燥物又は乾燥粉末の製法は大
別すれば次のとおりである。The conventional methods for producing a dried product or a dry powder of earthworms are roughly classified as follows.
iミミズの腹部を裂いて体内の内容物(内臓と泥土)を
とり去って天日、日陰又は低温(通常50℃以下)で乾燥
する方法。i A method in which the abdomen of earthworms is torn to remove the contents (internal organs and mud) inside the body and dried in the sun, shade or at low temperature (usually below 50 ° C).
iiミミズを草木灰の中に入れて殺したのち、灰をとり去
って天日、日陰又は低温(通常50℃以下)で乾燥し、ミ
ミズ体内に泥土がつまったままのものを得る方法。ii) A method in which earthworms are killed by putting them in plant ash, and then the ash is removed and dried in the sun, in the shade or at a low temperature (usually 50 ° C or lower) to obtain earthworms in which mud is clogged.
iiiミミズ体内の泥土をとり去ったのち、草木灰又は火
灰の中に入れて乾燥する方法。iii A method of removing mud from the body of an earthworm and then putting it in plant ash or fire ash to dry it.
などである。これらの乾燥物は必要時又は使用時に粉砕
して使用していた。これらの製法は簡易かつ経済的な方
法で、家庭でも安易に実行できる長所がある。And so on. These dried products were crushed and used when needed or used. These manufacturing methods are simple and economical methods, and have the advantage that they can be easily executed at home.
然しながら、これらの製法で得たミミズの乾燥物又は乾
燥粉末は0〜5℃の冷蔵庫内、又は5〜45℃の室温に開
放状態で貯蔵したとき約6ケ月以内、密閉状態で貯蔵し
たとき1年以内の短期間内に黴が発生し使用不可能とな
る欠点がある。However, the dried product or dry powder of earthworms obtained by these production methods is stored in a refrigerator at 0 to 5 ° C, or at room temperature of 5 to 45 ° C in an open state for about 6 months or less, and when stored in a sealed state. It has the drawback that it becomes unusable due to the growth of mold within a short period of less than a year.
前記iiの製法のように、体内に泥土がつまったまま乾燥
したミミズ、又はiiiの製法のように草木灰もしくは火
灰の中で乾燥したミミズは、薬として用いるときにはほ
とんどの場合、熱水で抽出又は煮沸水で煎じたのち過
し、液を服用することが多い。特にiiの製法によるミ
ミズの乾燥物又は乾燥粉末は地竜チンキ又は粉末のま
ま、もしくは丸薬などにして服用することが稀である。
iの製法によるミミズは、熱水浸せき液、煎じ液として
服用する他に、地竜チンキ又は地竜粉末のまま、もしく
は粉末に少量の水もしくは少量の賦形剤を加えて丸薬と
して服用することが多い。i及びiiの製法によるとき、
生きミミズから水分10〜16%の乾燥ミミズの収率は5〜
9%、同じくiiの製法によるときの収率は13〜19%(本
発明者らの実測値)である。Earthworms dried with mud clogged in the body as in the above method ii or earthworms dried in plant ash or fire ash as in the method iii are extracted with hot water in most cases when used as medicines. Or, after decocting with boiling water, the solution is often taken. In particular, the dried product or dried powder of earthworms produced by the method of ii is rarely taken as a ground dragon tincture or powder, or as a pill.
In addition to taking the earthworms produced by the method i as hot water dip or decoction, take the earth dragon tincture or earth dragon powder as it is, or add a small amount of water or a small amount of excipient to the powder and take it as a pill. There are many. According to the manufacturing method of i and ii,
The yield of dry earthworms with water content of 10 ~ 16% is 5 ~ from live earthworms.
9%, and the yield in the case of the production method of ii is 13 to 19% (measured value by the present inventors).
最近、本発明者の一人である石井陽一は、ミミズの蛋白
質及び脂質を主成分とする健康食品又はその製造法〔日
本特許出願公開公報昭59−216572号(公開日1984年12月
6日)〕を報告した。この製法は、健康食品としてのミ
ミズ乾燥粉末を得るためには、一つのすぐれた方法であ
る。然し、動脈硬化剤(別名抗高脂血症剤)、糖尿病治
療剤及び血圧降下剤などの薬用を目的としたミミズ乾燥
粉末の製法としては、薬効の点で十分でないことが判明
した。すなわち、生きミミズの生体内に残っている排泄
物を除去するために外的な作用を施すときには、糞土の
みを選択的に除去することができない。いくら注意深く
操作しても、薬効上、重要な役割をなす成分を多く含有
する内臓及び体液が、糞土と一緒に除去されるので薬効
不足となることがわかった。又、生きミミズに対する収
率は10〜19%と少ない。更に、大きな問題は、最終仕上
げ工程の真空乾燥を80℃、0.3トールの真空度で20時間
以上の長時間操作するために、薬理・薬効上、重要な作
用をなすミミズ乾燥粉末中の酵素類が破壊又は失活する
ことがわかった。従って、本発明の製法で得られたミミ
ズ乾燥粉末に比較すると、日本特許出願公開公報昭59−
216572号で得たミミズ乾燥粉末の糖尿病治療剤の薬効は
約50%であった。Recently, one of the inventors of the present invention, Yoichi Ishii, is a health food mainly composed of earthworm proteins and lipids or a method for producing the same [Japanese Patent Application Publication No. 59-216572 (published on Dec. 6, 1984). ] Was reported. This manufacturing method is one of the excellent methods for obtaining earthworm dry powder as a health food. However, it has been found that the method for producing an earthworm dry powder for medicinal purposes such as an arteriosclerotic agent (also known as an antihyperlipidemic agent), an antidiabetic agent and an antihypertensive agent is not sufficient in terms of efficacy. That is, when an external action is applied to remove the excrement remaining in the living body of living earthworm, it is not possible to selectively remove only the fecal soil. It was found that no matter how carefully the procedure is carried out, visceral and body fluids, which contain many components that play an important role in drug efficacy, are removed together with feces and soil, resulting in insufficient drug efficacy. The yield for live earthworms is as low as 10 to 19%. Furthermore, a major problem is that the enzymes in the dry earthworm powder, which have important pharmacological and medicinal effects, are used because the vacuum drying in the final finishing step is carried out at 80 ° C and a vacuum degree of 0.3 torr for a long time of 20 hours or more. Were found to be destroyed or deactivated. Therefore, in comparison with the earthworm dry powder obtained by the production method of the present invention, Japanese Patent Application Publication No. 59-
The effectiveness of the earthworm dry powder obtained in No. 216572 as a therapeutic agent for diabetes was about 50%.
最近、本発明者の一人である美原恒とその他の共同研究
者等により、ミミズの線溶活性物質は至適pHが8〜10、
安定pHが5〜10、トラジロール(商標名)、トランサミ
ン(商標名)、大豆トリプシンインヒビター及び血清で
阻害され、プラスミノーゲン活性化作用及びフイブリン
溶解作用を有し、フイビリノーゲン溶解作用を有しない
諸性質を保有する酵素蛋白質であることが確認された。Recently, one of the present inventors, Hisashi Mihara and other collaborators have found that the earthworm's fibrinolytic active substance has an optimum pH of 8-10,
Stable pH of 5 to 10, trasylol (trade name), transsamine (trade name), soybean trypsin inhibitor and serum-inhibited, plasminogen activating action and fibrinolytic action, and various substances without fibrinogen lytic action It was confirmed to be an enzyme protein having properties.
ミミズからの水性溶媒の抽出法による粗製酵素蛋白質画
分と、その精製処理による糖製酵素蛋白質画分からなる
線溶活性物質の製造法の出願特許即ち、日本特許出願公
開公報昭58−148824号(出願日1982年2月27日)と、こ
れの優先権主張による外国出願のアメリカ特許出願No.4
70394(出願日1983年2月28日)、イギリス特許出願No.
8305359(出願日1983年2月25日)、イタリア特許出願N
o.47795A(出願日1983年2月25日)、フランス特許出願
No.03165(出願日1983年2月25日)、西ドイツ特許出願
No.P3306944.1(出願日1983年2月28日)及びカナダ特
許出願No.422034(出願日1983年2月21日)が報告され
ている。Patent application of a method for producing a fibrinolytic active substance consisting of a crude enzyme protein fraction by an extraction method of an aqueous solvent from earthworm and a sugar enzyme protein fraction by the purification treatment, that is, Japanese Patent Application Publication No. 58-148824 ( Filing date: February 27, 1982) and US patent application No. 4 of a foreign application due to the priority claim
70394 (filing date February 28, 1983), British patent application No.
8305359 (filing date February 25, 1983), Italian patent application N
o.47795A (filing date February 25, 1983), French patent application
No.03165 (filing date February 25, 1983), West German patent application
No. P3306944.1 (filing date February 28, 1983) and Canadian patent application No. 422034 (filing date February 21, 1983) are reported.
さらに、美原恒らによりミミズからの6種の新規なプロ
テアーゼの物質特許の出願、即ち日本特許出願公開公報
昭59−63184号(出願日、昭和57(1982)年10月2日)
及びこれらのプロテアーゼを有効成分とする血栓溶解剤
の特許出願即ち、日本特許出願公開公報昭59−184131号
(出願日、昭和58(1983)年3月31日)と、これらの併
合出願の優先権主張の外国特許出願即ち、韓国特許出願
第2990号(出願日1983年6月30日)をはじめ次の特許出
願が報告(AU.P.App.16293(出願日1983年6月27日)、
CA.P.App.431387(出願日1983年6月28日)、DK.P.App.
3008(出願日1983年6月29日)、EP.P.App.83106288.0
(出願日1983年6月28日)、EP.P.App.523754(出願日1
983年6月30日)、FI.P.App.832383(出願日1983年6月
29日)、No.P.App.2399(出願日1983年6月30日)、PH.
P.App.29151(出願日1983年6月30日)、TW.P.App.7211
983(出願日1983年6月18日)、US.P.App.508163(出願
日1983年6月27日)〕されている。Furthermore, the application for substance patents of 6 kinds of novel proteases from earthworm by Tsuneyoshi Mihara, that is, Japanese Patent Application Publication No. 59-63184 (filing date, October 2, 1982)
And a patent application for a thrombolytic agent containing these proteases as active ingredients, that is, Japanese Patent Application Publication No. Sho 59-184131 (filing date: March 31, 1983), and priority of these merged applications. Foreign patent applications claiming rights, that is, Korean patent application No. 2990 (filing date June 30, 1983) and the following patent applications (AU.P.App.16293 (filing date June 27, 1983)) ,
CA.P.App.431387 (filing date June 28, 1983), DK.P.App.
3008 (filing date June 29, 1983), EP.P.App.83106288.0
(Filing date June 28, 1983), EP.P.App.523754 (filing date 1
June 30, 983), FI.P.App.832383 (application date June 1983)
29th), No.P.App.2399 (filing date June 30, 1983), PH.
P.App.29151 (filing date June 30, 1983), TW.P.App.7211
983 (filing date June 18, 1983), US.P.App.508163 (filing date June 27, 1983)].
本発明者等の調査結果では、ミミズの乾燥粉末及びミミ
ズの抽出物を有効成分とする糖尿病治療・予防剤又は血
糖低下剤の作用活性を報告した文献を見出すことができ
なかつた。As a result of the investigation by the present inventors, it was not possible to find a document that reported the action activity of a diabetes treatment / prevention agent or a hypoglycemic agent containing an earthworm dry powder or an earthworm extract as an active ingredient.
すなわち、アロキサンによる実験的糖尿病マウスにミミ
ズの乾燥粉末及びミミズの抽出物を投与したとき、有意
に血糖値を低下させることを報告した文献を見出すこと
ができなかつた。That is, it was not possible to find a literature that reported that the blood glucose level was significantly lowered when the dry powder of earthworm and the extract of earthworm were administered to experimental diabetic mice caused by alloxan.
又、ヒトの糖尿病患者に食事療法と共に、ミミズ乾燥粉
末を4〜9ケ月間投与した。特に軽・中程度の糖尿病患
者の場合には、投与2〜3ケ月後から血糖値は改善さ
れ、投与4ケ月後以降からは健康人の標準値まで血糖を
降下させることができたなど、このすぐれた効果を報告
した文献を見出すことができなかつた。In addition, earthworm dry powder was administered to human diabetic patients along with diet for 4 to 9 months. Especially in the case of mild / moderate diabetic patients, the blood glucose level improved from 2 to 3 months after administration, and it was possible to lower the blood glucose to the standard value of healthy people from 4 months after administration. We could not find any literature that reported excellent effects.
更に、かかる効果をもつミミズの乾燥粉末及びミミズの
抽出物の製法を報告した文献を見出すことができなかつ
た。Furthermore, it was not possible to find a document reporting a method for producing a dry powder of earthworm and an extract of earthworm having such an effect.
発明が解決しようとする問題点: 従来から経口的糖尿病治療剤としては、スルフオニルウ
レア(Sulfonyl urea)及びビグアニド(Biguanide)化
合物などの有機合成化合物が広く用いられている。Problems to be Solved by the Invention: Organic synthetic compounds such as sulfonyl urea and biguanide compounds have been widely used as oral therapeutic agents for diabetes.
本発明者らは、このような合成有機化合物の中からでは
なく、天然物から副作用のない安全性の高い医薬品の創
製を目的としてミミズ乾燥粉末の利用について長年鋭意
研究してきた。意外にもミミズの乾燥粉末及びミミズの
抽出物が糖尿病治療・予防に有効であることを見い出
し、本発明を完成したものである。The inventors of the present invention have long earnestly studied the use of earthworm dry powder for the purpose of creating a highly safe drug without side effects, not from such synthetic organic compounds, but from natural products. Surprisingly, they have found that dry earthworm powder and earthworm extract are effective for the treatment and prevention of diabetes, and completed the present invention.
問題点を解決するための手段 本発明はミミズの乾燥物を一部の形態として含むミミズ
の乾燥粉末;ミミズを水性溶媒、水混和性有機溶媒(水
と混和する性状の有機溶媒の意味。)及び水非混和性有
機溶媒(水と混和しない性状の有機溶媒の意味。)から
なる群から選ばれる少なくとも一種類の抽出剤によって
抽出処理して得たミミズの抽出物を有効成分として含有
する糖尿液治療・予防剤に関する。さらに、安全ですぐ
れた糖尿病治療効果を有し、かつ、密閉状態で少なくと
も4年間貯蔵又は保管が可能な無菌ミミズの乾燥粉末を
高い収率で得るために詳細に研究した結果、次に示す新
規でかつ進歩性のある改良製法を確立した。Means for Solving the Problems The present invention relates to a dry powder of earthworm which contains a dried product of earthworm as a part of the form; an aqueous solvent of the earthworm, a water-miscible organic solvent (meaning an organic solvent which is miscible with water). And a water-immiscible organic solvent (meaning an organic solvent that is immiscible with water) containing at least one extractant selected from the group consisting of earthworms as an active ingredient. Urine fluid treatment / prevention agent. Furthermore, as a result of detailed studies to obtain a high yield of a dry powder of sterile earthworm which has a safe and excellent therapeutic effect on diabetes and can be stored or stored in a sealed state for at least 4 years, the following novel And an improved manufacturing method with an inventive step was established.
製法1.: 生きミミズを真水中又は酢酸、クエン酸、コハク酸、リ
ンゴ酸、酒石酸、乳酸などの有機酸又はリン酸、硫酸、
塩酸などの無機酸またはこれらの酸のナトリウム又はカ
リウム塩の少なくとも1種類の化合物を0.3(重量)%
以下含有好ましくは0.1(重量)%以下含有の低濃度又
はpH3〜6.5の微酸性の水溶液中に温度1〜25℃にて0.5
〜72時間、好ましくは温度2〜15℃、1〜40時間放置し
て生きミミズ自身が有する排泄力によって生きミミズの
消化管内の糞土を十分排泄させたのち、水で生きミミズ
の体表面に付着している汚物を洗い落とし、湿式粉砕を
行なつた。湿式粉砕されたミミズを−5℃以下の低温、
好ましくは−10〜−60℃の低温で凍結したのち、次に凍
結・真空乾燥を行なつた。凍結・真空乾燥の条件は温度
−60〜+90℃、真空度100mmHg以下、好ましくは−40〜
+80℃で30mmHg以下の真空度で温度は階段的に上げなが
ら5〜100時間好ましくは10〜60時間凍結・真空乾燥を
行なつて無菌のミミズの乾燥粉末を得た。Production method 1: Live earthworms in fresh water or organic acids such as acetic acid, citric acid, succinic acid, malic acid, tartaric acid, lactic acid, or phosphoric acid, sulfuric acid,
0.3 (wt)% of at least one compound of inorganic acid such as hydrochloric acid or sodium or potassium salt of these acids
0.5% at a temperature of 1 to 25 ° C in a low-concentration or slightly acidic aqueous solution of pH 3 to 6.5 containing 0.1% by weight or less.
~ 72 hours, preferably at a temperature of 2-15 ° C for 1-40 hours, to excrete the fecal soil in the digestive tract of live earthworms by the excretion power of live earthworms themselves, and then attach it to the body surface of live earthworms with water. The remaining filth was washed off and wet pulverization was performed. Wet-ground earthworms at a low temperature of -5 ° C or lower,
After freezing, preferably at a low temperature of -10 to -60 ° C, freeze / vacuum drying was performed. Freezing and vacuum drying conditions are temperature -60 to + 90 ° C, vacuum degree 100mmHg or less, preferably -40 to
Freezing and vacuum drying were carried out for 5 to 100 hours, preferably 10 to 60 hours, while raising the temperature stepwise at + 80 ° C. and a vacuum degree of 30 mmHg or less to obtain a sterile powder of earthworm.
製法2: 生きミミズの体表面に付着している汚物を水で洗い落と
したのち、真水中又は酢酸、クエン酸、コハク酸、リン
ゴ酸、酒石酸、乳酸などの有機酸又はリン酸、硫酸、塩
酸などの無機酸又はこれらの酸のナトリウム又はカリウ
ム塩の少なくとも1種類の化合物を0.3(重量)%以下
含有好ましくは0.1(重量)%以下含有の低濃度又はpH3
〜6.5の微酸性の水溶液中に、温度1〜25℃にて、0.5〜
72時間好ましくは温度2〜15℃にて1〜40時間放置して
生きミミズ自身が有する排泄力によって、生きミミズの
消化管内の糞土を十分排泄させたのち、湿式粉砕を行な
つた。湿式粉砕されたミミズを−5℃以下の低温、好ま
しくは−10〜−60℃の低温で凍結したのち、次に凍結・
真空乾燥を行なつた。この凍結・真空乾燥の条件は温度
−60〜+90℃、真空度100mmHg以下、好ましくは−40〜
+80℃、30mmHg以下の真空度で温度を階段的に上げなが
ら5〜100時間好ましくは10〜60時間凍結・真空乾燥を
行なつて無菌のミミズの乾燥粉末を得た。Process 2: After washing away the dirt attached to the body surface of live earthworms with water, fresh water or organic acids such as acetic acid, citric acid, succinic acid, malic acid, tartaric acid, lactic acid or phosphoric acid, sulfuric acid, hydrochloric acid, etc. Inorganic acid or at least one compound of sodium or potassium salt of these acids is contained in an amount of 0.3 (wt)% or less, preferably 0.1 (wt)% or less in low concentration or pH 3
0.5 to 6.5 in slightly acidic aqueous solution at 1 to 25 ° C
After leaving for 72 hours, preferably at a temperature of 2 to 15 ° C. for 1 to 40 hours, the excrement power of the live earthworm itself excreted the fecal soil in the digestive tract of the live earthworm, and then wet grinding was performed. Wet-ground earthworms are frozen at a low temperature of -5 ° C or lower, preferably -10 to -60 ° C, and then frozen.
Vacuum drying was performed. The freezing and vacuum drying conditions are a temperature of -60 to + 90 ° C and a vacuum degree of 100 mmHg or less, preferably -40 to
Freezing and vacuum drying were carried out for 5 to 100 hours, preferably 10 to 60 hours while raising the temperature stepwise at + 80 ° C. and a vacuum degree of 30 mmHg or less to obtain a sterile dry powder of earthworms.
ミミズの湿式粉砕方法、即ち、ミミズの組織(細胞)破
壊方法としては、ホモジナイザー、ブレンダー、ホモミ
キサー、擂漬機、加圧型細胞破壊装置の機器を利用して
懸濁液又は均質液とすることが好ましい。この湿式粉砕
時の温度は1〜25℃好ましくは2〜15℃が望ましい。As a method for wet grinding of earthworms, that is, a method for destroying the tissue (cells) of earthworms, use a homogenizer, a blender, a homomixer, a pickling machine, or a pressure-type cell disruption device to prepare a suspension or homogeneous solution. Is preferred. The temperature during this wet pulverization is preferably 1 to 25 ° C, preferably 2 to 15 ° C.
前記の操作により生きたミミズから黄褐色又は褐色のミ
ミズ乾燥粉末を収率20〜35%で得ることができた。通常
の場合、このミミズ乾燥粉末の水分は5〜16%好ましく
は7〜14%、灰分は3〜8%好ましくは4〜7%、窒素
は1〜11%好ましくは6〜11%含有するように調製し
た。又、ミミズ乾燥粉末中にはアスパラギン酸、スレオ
ニン、セリン、グルタミン酸、プロリン、グリシン、ア
ラニン、システイン、バリン、メチオニン、イソロイシ
ン、ロイシン、チロシン、フエニルアラニン、トリプト
フアン、リジン、ヒスチジン、アルギニンの18種類又は
それ前後のアミノ酸を含有する。By the above-mentioned procedure, yellow-brown or brown earthworm dry powder could be obtained from living earthworms in a yield of 20 to 35%. Usually, the water content of this earthworm dry powder is 5 to 16%, preferably 7 to 14%, ash content is 3 to 8%, preferably 4 to 7%, and nitrogen content is 1 to 11%, preferably 6 to 11%. Was prepared. Further, in the earthworm dry powder, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, tryptophan, lysine, histidine, arginine 18 kinds or It contains the amino acids before and after it.
試験例1 前記製法1及び2の方法で得たミミズ乾燥粉末の粗分析
結果を表−1に示す。Test Example 1 Table 1 shows the results of rough analysis of the dried earthworm powder obtained by the above-mentioned production methods 1 and 2.
試験例2 製法1の方法で得たM−2とM−4及び製法2の方法で
得たM−5のミミズ乾燥粉末製品の成分分析結果を表−
2に示す。 Test Example 2 Table 2 shows the component analysis results of the M-2 and M-4 obtained by the method of the production method 1 and the M-5 dried earthworm powder product obtained by the method of the production method 2.
2 shows.
試験例3 製法1の方法で得たM−2とM−4及び製法2の方法で
得たM−5のミミズ乾燥粉末製品中の粗蛋白質のアミノ
酸分析をおこない、蛋白食品のフイシユミール及び大豆
粉の分析値と比較した結果を表−3に示した。 Test Example 3 M-2 and M-4 obtained by the method of production method 1 and M-5 obtained by the method of production method 2 were subjected to amino acid analysis of the crude protein in the earthworm dry powder product to obtain protein foods, fish meal and soybean flour. The results of comparison with the analytical values of are shown in Table-3.
表−2及び表−3より、製法1及び2の方法により得た
ミミズ乾燥粉末中には粗蛋白質、粗脂質及び各種金属類
が豊富に含有していることがわかり、又、粗蛋白質中の
アミノ酸組成では必須アミノ酸を多量に含有しているこ
とがわかった。 From Table-2 and Table-3, it was found that the earthworm dry powders obtained by the methods of Production Methods 1 and 2 were rich in crude protein, crude lipid and various metals, and also in the crude protein. It was found that the amino acid composition contained a large amount of essential amino acids.
前記製法1の方が、製法2で得られたミミズ乾燥粉末よ
りも、若干好ましい製品が得られた。又、前記の有機酸
又は無機酸又はこれらの両酸のナトリウム又はカリウム
塩の少なくとも1種類の化合物を上記のような低濃度に
含む水溶液中に生きミミズを放置した方が、真水中に放
置するよりも生きミミズの消化管内の糞土の排泄が早く
かつ、排泄率が大きい。The production method 1 yielded a slightly more preferable product than the earthworm dry powder obtained in the production method 2. Further, it is better to leave live earthworms in an aqueous solution containing the above-mentioned organic acid or inorganic acid or at least one compound of sodium or potassium salt of these both acids in a low concentration as described above, to leave it in fresh water. Excretion of fecal soil in the digestive tract of live earthworms is faster and the excretion rate is higher than that of live earthworms.
前記の製法1及び2において乾燥終了後のミミズ乾燥物
製品の仕上り状態は集合状態又は固まりが混合した状態
となっていることが多い。然し、これを粉砕機にかける
と容易に粉末となる。ミミズの乾燥物及びミミズの抽出
物をヒトを含め哺乳動物に投与するときには固まりより
も粉末の方が好ましい。In the above-mentioned production methods 1 and 2, the finished state of the earthworm dried product after the completion of the drying is often an aggregated state or a state in which lumps are mixed. However, when it is crushed, it easily becomes a powder. When the dried earthworm and the extract of earthworm are administered to mammals including humans, the powder is preferable to the mass.
が発生し使用不可能となる欠点がある。However, there is a drawback that it becomes unusable.
美原恒ら〔日本特許出願公開公報昭59−63184号及び昭5
9−184131号〕は、ミミズから線溶酵素の6種の新規プ
ロテアーゼを分画した。即ち、美原恒らはミミズ乾燥粉
末に10倍量の生理的食塩水を加えて2日間のインキユベ
ーシヨン(Incubation)を行なつた上清液について硫安
分画を行なつたのち、その沈渣をSephacryl S−200によ
るゲル過を行ない、得られた蛋白分画についてDEAE−
セルロースイオン交換クロマトグラフイーを行なつた結
果、カゼイン分解とフイブリン分解活性を有するI、I
I、III分画の蛋白を得た。このI、II、IIIの分画につ
いて更にDEAE−セルロース、Sephadex G−75、トヨパー
ルHW55、ACH−Sepharose、Benzamidine−Sepharoseなど
による精製処理を行なつた結果、6分画の精製酵素を得
た。SDS−PAGEで分子量を測定すると分画I−0の分子
量が一番低く、23,500と計算され、その後、順次にI−
1、I−2、II、III−1、III−2と分子量が増加し、
III−2は分子量34,200であつた。また等電点電気泳動
でこの6分画の等電点を測定するとI−0が最も高く、
pH4.12であり、その後、順次pHは低くなり、III−2でp
H3.52であつた。これらの6分画はセリン酵素とも異な
る新しい蛋白分解酵素であり、また、これらの6分画の
蛋白分解酵素の至適pHは8付近またはpH8〜10、安定pH
は4〜12または5〜12、至適温度50℃または50〜60℃、
失活条件は70℃で60分間であつたと報告されている。Mihara Tsune et al. [Japanese Patent Application Publication No. Sho 59-63184 and Sho 5]
9-184131], fractionated six novel proteases of fibrinolytic enzymes from earthworms. In other words, Mihara, et al. Added ammonium sulphate to 10 times the amount of physiological saline to the earthworm powder and incubated it for 2 days. The supernatant was subjected to ammonium sulfate fractionation, and then the precipitate. Gel separation with Sephacryl S-200 was performed.
Cellulose ion-exchange chromatography showed that I and I with casein-degrading and fibrin-degrading activities.
Proteins of I and III fractions were obtained. The fractions I, II and III were further purified with DEAE-cellulose, Sephadex G-75, Toyopearl HW55, ACH-Sepharose, Benzamidine-Sepharose and the like to obtain 6 fractions of purified enzyme. When the molecular weight was measured by SDS-PAGE, the molecular weight of the fraction I-0 was the lowest, and it was calculated to be 23,500.
1, I-2, II, III-1, III-2 and molecular weight increase,
III-2 had a molecular weight of 34,200. Moreover, when the isoelectric point of these 6 fractions was measured by isoelectric focusing, I-0 was the highest,
The pH was 4.12.
It was H3.52. These 6-fractions are new proteases different from serine enzymes, and the optimum pH of these 6-fraction proteolytic enzymes is around 8 or pH 8-10, stable pH.
Is 4-12 or 5-12, the optimum temperature is 50 ℃ or 50-60 ℃,
The quenching condition is reported to have been 70 ° C. for 60 minutes.
前記の製法1及び2で得たミミズの乾燥粉末製品M−4
及びM−5に10倍量の生理的食塩水を加え、その上清を
標準フイブリン平板で測定すると、表−4に示すよう
に、直ぐに線溶活性が認められた。このM−4のミミズ
乾燥粉末の生理的食塩水溶液を37℃でインキユベートし
ておくと、表−4に示すようにその上清の線溶活性は10
日目で約4倍となり、50日目で5倍、75日目で5.5倍と
なる。この事実は、ミミズの凍結乾燥粉末中にはこの蛋
白分解酵素の前駆物質が大量に存在し、自己消化により
酵素活性の発現があるものと考えられる。この50日目の
上清の活性をウロキナーゼの国際単位に換算して比較す
ると約8,000IU/mlと計算された。また、この酵素はプラ
スミノゲン・フリーフイブリン平板、標準フイブリン平
板とも溶解し、標準フリブリン平板の方がプラスミノゲ
ン・フリー平板に比較して溶解窓が大きく、フイブリン
を直接分解する酵素活性とともに、プラスミノゲン・ア
クチベータ活性も示された。前記操作において、M−4
の代りに、M−5のミミズ乾燥粉末を用いて測定した結
果は表−4と同一結果が得られた。Earthworm dry powder product M-4 obtained by the above-mentioned production methods 1 and 2
When 10 times the amount of physiological saline was added to M-5 and M-5, and the supernatant was measured with a standard fibrin plate, fibrinolytic activity was immediately observed as shown in Table 4. When the physiological saline solution of the earthworm dry powder of M-4 was incubated at 37 ° C, the fibrinolytic activity of the supernatant was 10 as shown in Table-4.
It becomes about 4 times on the day 5, 5 times on the 50th day, and 5.5 times on the 75th day. This fact is considered to be because a large amount of this proteolytic enzyme precursor is present in the lyophilized powder of earthworm, and the enzyme activity is expressed by autolysis. When the activity of the supernatant on the 50th day was converted into international units of urokinase and compared, it was calculated to be about 8,000 IU / ml. This enzyme also dissolves both plasminogen-free fibrin plates and standard fibrin plates, and the standard frybrin plates have a larger dissolution window than plasminogen-free plates, and the enzyme activity that directly decomposes fibrin, as well as the plasminogen activator activity. Was also shown. In the above operation, M-4
The same results as in Table 4 were obtained as a result of measurement using M-5 earthworm dry powder instead of.
本発明品のミミズ乾燥粉末及びミミズの抽出物をラツト
及びヒトへ経口投与することにより糖尿病治療・予防効
果又は血糖降下作用効果を示す理由についての詳細は不
明であるが、ミミズの乾燥粉末及びミミズの抽出物中に
含有されている蛋白分解酵素(蛋白質)自体又はこの酵
素の前駆物質(蛋白質)自体もしくは蛋白質又は脂質物
質もしくはその他の未知化合物自体又はこれらの併合の
作用によるものと考えられる。糖尿病治療剤として最も
好ましい本発明品のミミズ乾燥粉末の窒素含量は7〜10
%、即ち粗蛋白含量43.8〜62.5%のものである。 The details of the reason why the dry earthworm powder of the present invention and the extract of earthworm have diabetes treatment / preventive effect or hypoglycemic effect by oral administration to rat and human are unknown, but the dry earthworm powder and earthworm It is considered that it is due to the proteolytic enzyme (protein) itself or the precursor of this enzyme (protein) itself or the protein or lipid substance or other unknown compound itself contained in the extract of (1) or the combination thereof. The nitrogen content of the earthworm dry powder of the present invention most preferred as a therapeutic agent for diabetes is 7-10.
%, That is, a crude protein content of 43.8 to 62.5%.
次に前記の製法1及び2の方法で得たミミズの湿式粉砕
による懸濁液の凍結・真空乾燥操作の好ましい具体例を
示すと次のとおりである。Next, a preferable specific example of the freeze / vacuum drying operation of the suspension obtained by the wet pulverization of earthworms obtained by the above-mentioned production methods 1 and 2 is as follows.
ミミズの湿式粉砕物すなわち、ミミズの懸濁液を−10〜
−60℃好ましくは−30〜−50℃で5〜60時間凍結したの
ち、同温度で0.01〜0.2mmHgの真空下、5〜12時間の凍
結乾燥する。次に20〜30℃で5〜15時間、0.01〜0.2mmH
gの真空下で乾燥する。次に35〜50℃、0.1〜0.5mmHgの
真空下で10〜20時間乾燥する。次の最終仕上げ工程の真
空乾燥は、0.01〜0.5mmHgの真空下、70〜80℃好ましく
は75〜80℃で5〜10時間真空乾燥すると無菌で且つ水分
5〜15%含有のミミズ乾燥粉末を得ることができた。特
に最終仕上げの真空乾燥が重要操作である。ミミズ乾燥
粉末中に含まれる蛋白分解酵素及びその酵素の前駆物質
の活性を失活させることがなく、ミミズの乾燥粉末を無
菌状態に仕上げるために本発明者は詳細に研究した結
果、凍結・真空乾燥の最終工程の真空乾燥条件の真空
度、加温温度、時間の3要素の組合わせが重要条件であ
ることを見出し、前記の運転条件を確立した。Wet ground product of earthworms, that is, earthworm suspension -10 ~
After freezing at −60 ° C., preferably −30 to −50 ° C. for 5 to 60 hours, it is freeze-dried at the same temperature under a vacuum of 0.01 to 0.2 mmHg for 5 to 12 hours. Next, at 20-30 ℃ for 5-15 hours, 0.01-0.2mmH
Dry under vacuum of g. Next, it is dried at 35 to 50 ° C. under a vacuum of 0.1 to 0.5 mmHg for 10 to 20 hours. Vacuum drying in the next final finishing step is performed under vacuum of 0.01 to 0.5 mmHg at 70 to 80 ° C., preferably 75 to 80 ° C. for 5 to 10 hours to obtain a sterile earthworm dry powder containing 5 to 15% of water content. I was able to get it. Especially, vacuum drying for final finishing is an important operation. The present inventors have studied in detail in order to make the dry powder of the earthworm aseptic without deactivating the activities of the protease and the precursor of the enzyme contained in the dry powder of the earthworm, and as a result, freeze-vacuum. It was found that the combination of the three factors of vacuum degree, heating temperature and time of the vacuum drying conditions in the final step of drying is an important condition, and the above operating conditions were established.
前記に示すように、ミミズ乾燥粉末からの精製蛋白分解
酵素の6種共(日本特許出願公開公報昭59−63184号及
び昭59−184131号)70℃、60分間で失活することが報告
されているが、本発明の製法で得たミミズ乾燥粉末中の
蛋白分解酵素は表−4に示すように失活されていない。As described above, all six proteolytic enzymes purified from earthworm dry powder (Japanese Patent Application Publication Nos. 59-63184 and 59-184131) were reported to be inactivated at 70 ° C for 60 minutes. However, the proteolytic enzyme in the earthworm dry powder obtained by the production method of the present invention is not inactivated as shown in Table 4.
製法1及び2の方法で得たミミズ乾燥粉末は、5〜45℃
の室温に密閉状態に5年間、保存した例では、黴の発生
その他の変質は全く認められなかった。Earthworm dry powder obtained by the methods 1 and 2 is 5 to 45 ° C.
In the case where the sample was stored at room temperature in a sealed state for 5 years, no generation of mold and other alterations were observed.
本発明の糖尿病治療剤のミミズ乾燥粉末の形態は、前記
の製法1及び2で得たミミズ乾燥粉末のほかに、従来の
公知のi,ii,iiiの製法により得たミミズの乾燥物及び
その乾燥粉末でもよい。The form of the earthworm dry powder of the therapeutic agent for diabetes of the present invention is, in addition to the earthworm dry powder obtained by the above-mentioned production methods 1 and 2, a dried product of earthworms obtained by the conventionally known production methods i, ii, and iii, and the same. It may be a dry powder.
又、糖尿病治療剤のミミズの抽出物は、次の製造方法に
より得ることができる。The earthworm extract, which is a therapeutic agent for diabetes, can be obtained by the following production method.
原料のミミズを水性溶媒、水混和性有機溶媒及び水非混
和性有機溶媒からなる群から選ばれる少なくとも一種類
の抽出剤によって抽出処理し、得られた抽出液を濃縮し
て沈澱物として析出せしめるか、又は濃縮抽出液に他種
もしくは同種の有機溶媒を加えて沈澱物として得るか、
もしくは常圧、加圧又は減圧下で抽出溶媒を完全に除去
して抽出物を得た。The earthworm as a raw material is subjected to extraction treatment with at least one kind of extractant selected from the group consisting of an aqueous solvent, a water-miscible organic solvent and a water-immiscible organic solvent, and the obtained extract is concentrated to precipitate as a precipitate. Or, to obtain a precipitate by adding the organic solvent of the other kind or the same kind to the concentrated extract,
Alternatively, the extraction solvent was completely removed under normal pressure, increased pressure or reduced pressure to obtain an extract.
原料のミミズは、前記の製法1及び2で得たミミズ乾燥
粉末;前記のi,ii及びiiiの公知の製法で得たミミズの
乾燥物及びその乾燥粉末;糞土を除去したもの又は糞土
を含んで生きミミズもしくは、これらのなまミミズ;こ
れらの生きミミズ及び/又はなまミミズの粉砕懸濁液な
どの形状のミミズを使用することができる。The earthworms of the raw material include the earthworm dry powder obtained by the above-mentioned production methods 1 and 2; the dried earthworm product obtained by the known production method of i, ii and iii and its dry powder; It is possible to use live earthworms or earthworms of these shapes; earthworms in the form of live earthworms and / or ground suspensions of ground earthworms.
これらの内、最も好ましい原料ミミズの形態は、前記の
製法1及び2の操作処理工程において湿式粉砕をおこな
って得たミミズの懸濁液である。Of these, the most preferable form of the material earthworm is a suspension of earthworms obtained by performing wet pulverization in the operation processing steps of the above-mentioned production methods 1 and 2.
すなわち、生きミミズを酢酸、クエン酸、コハク酸、リ
ンゴ酸、酒石酸又は乳酸からなる有機酸;リン酸、硫酸
又は塩酸からなる無機酸;これらの有機酸ナトリウム
塩;これらの有機酸カリウム塩;これらの無機酸ナトリ
ウム塩;これらの無機酸カリウム塩からなる群から選ば
れた少なくとも一種類の化合物を0.3(重量)%以下の
低濃度又はpH3〜6.5の微酸性の水溶液中又は真水中に放
置して生きミミズの消化管内の糞土をはかせたのち、生
きミミズの体表面に付着する汚物を水で洗浄除去して湿
式粉砕をおこなうか、又は、生きミミズの体表面に付着
する汚物を水で洗浄除去したのちの生きミミズを前記水
溶液中又は真水中に放置して生きミミズの消化管内の糞
土をはかせたのち、湿式粉砕をおこない、得たミミズの
ペースト状の懸濁液である。この懸濁液を原料としたと
きには、他の形態のミミズよりも溶媒の使用量が節約で
き、かつ、糖尿病治療剤としての有効物質を短時間に抽
出することができ、さらに処理時間単位当りの抽出物量
が多いなどの抽出効率がすぐれている。次に好ましい原
料形態は前記製法1及び2で得たミミズ乾燥粉末であ
る。That is, live earthworms are organic acids consisting of acetic acid, citric acid, succinic acid, malic acid, tartaric acid or lactic acid; inorganic acids consisting of phosphoric acid, sulfuric acid or hydrochloric acid; sodium salts of these organic acids; potassium salts of these organic acids; Inorganic acid sodium salt; at least one kind of compound selected from the group consisting of these inorganic acid potassium salts is left in a low concentration of 0.3 (wt)% or less or in a slightly acidic aqueous solution of pH 3 to 6.5 or in fresh water. After the fecal soil in the digestive tract of live earthworms is spread, the filth adhering to the body surface of the live earthworms is washed away with water and wet-milled, or the filth adhering to the body surface of the live earthworms is washed with water. After removing the live earthworms in the above-mentioned aqueous solution or in fresh water to spread the excrement in the digestive tract of the live earthworms, wet pulverization is performed, and a paste-like suspension of earthworms is obtained. . When this suspension is used as a raw material, the amount of solvent used can be saved more than other forms of earthworm, and the active substance as a therapeutic agent for diabetes can be extracted in a short time. Excellent extraction efficiency such as large amount of extract. The next preferable raw material form is the earthworm dry powder obtained by the above-mentioned manufacturing methods 1 and 2.
抽出溶媒の水性溶媒は、真水、蒸留水、生理食塩水、pH
5〜10の各種の緩衝液又は各種の調製水を用いるのが好
ましい。緩衝液はリン酸、酢酸、ホウ酸、クエン酸、ト
リス・塩酸などのpH5〜10好ましくはpH6〜8の各種組成
の緩衝液の一種以上が使用できる。又、pH5〜10好まし
くはpH6〜8の調製液とは塩酸、硫酸、リン酸、酢酸、
乳酸、クエン酸、コハク酸、リンゴ酸又は酒石酸などの
水溶性の無機酸、有機酸とナトリウム、カリウムなどの
アルカリ金属の水酸化物又は炭酸塩から自家調製した稀
薄水溶液を意味する。最も好ましい水性溶媒は生理食塩
水、緩衝液、真水である。これらの水性溶媒を使用する
ときには、パラヒドロキシ安息香酸エチルエステル、安
息香酸ナトリウム塩、アジ化ナトリウムなどの防腐剤を
0.01〜0.3(重量)%使用することが好ましい。Aqueous solvent of extraction solvent is fresh water, distilled water, physiological saline, pH
It is preferable to use 5 to 10 various buffers or various preparation waters. As the buffer solution, one or more buffer solutions having various compositions such as phosphoric acid, acetic acid, boric acid, citric acid, Tris / hydrochloric acid having a pH of 5 to 10, preferably pH 6 to 8, can be used. Further, the pH 5-10, preferably pH 6-8 preparation liquid is hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid,
It means a dilute aqueous solution prepared in-house from a water-soluble inorganic acid such as lactic acid, citric acid, succinic acid, malic acid or tartaric acid, an organic acid and an alkali metal hydroxide or carbonate such as sodium or potassium. The most preferred aqueous solvents are saline, buffer and fresh water. When using these aqueous solvents, preservatives such as para-hydroxybenzoic acid ethyl ester, benzoic acid sodium salt and sodium azide should be used.
It is preferable to use 0.01 to 0.3 (weight)%.
水混和性有機溶媒としては、例えば、メチル、エチル、
アリル、n−プロピル、i−プロピル、n−ブチル、s
−ブチル、又はt−ブチルアルコールなどの炭素数1〜
4の低級アルコール類;アセトン又はメチルエチルケト
ンなどの炭素数3〜4のケトン類;エチルエーテル、1,
2−プロピレンオキシド、ジオキソラン、4−メチルジ
オキソラン又はジオキサンなどの炭素数3〜4のエーテ
ル類;ギ酸メチル、ギ酸エチル、酢酸メチルなどの炭素
数2〜4のエステル類を用いるのが好ましい。これらの
内、最も好ましい水混和性有機溶媒は炭素数1〜4のア
ルコール類である。Examples of the water-miscible organic solvent include methyl, ethyl,
Allyl, n-propyl, i-propyl, n-butyl, s
-Butyl or t-butyl alcohol and the like having 1 to 1 carbon atoms
Lower alcohols of 4; ketones having 3 to 4 carbon atoms such as acetone or methyl ethyl ketone; ethyl ether, 1,
It is preferable to use C3-C4 ethers such as 2-propylene oxide, dioxolane, 4-methyldioxolane or dioxane; C2-C4 esters such as methyl formate, ethyl formate and methyl acetate. Of these, the most preferred water-miscible organic solvent is an alcohol having 1 to 4 carbon atoms.
水非混和性有機溶媒としては、例えば、n−ヘキサン、
i−ヘキサン、n−ヘプタン、i−ヘプタン、オクタ
ン、i−オクタン、シクロヘキサン、ベンゼン、トルエ
ン、キシレン又はエチルベンゼンなどの炭素数6〜10の
炭化水素類;n−ヘキシル、2−メチルペンチル、2−エ
チルブチル、s−ヘキシル、s−ヘプチル、n−オクチ
ル、2−エチルヘキシル、2,6−ジメチル−4−ヘプチ
ル、n−デシルアルコールなどの炭素数6〜10のアルコ
ール類;メチル−n−アミルケトン、メチルシクロヘキ
サノン又はメチルヘキシルケトンなどの炭素数7〜8の
ケトン類;酢酸s−ブチル、酢酸i−ブチル、酢酸−2
−エチルブチル、酢酸s−アミル又は酢酸メチルアミル
エステルなどの炭素数6〜8のエステル類;クロロホル
ム、ジクロルペンタン又はエピクロルヒドリンなどの炭
素数1〜5のハロゲン化炭水素類などを用いるのが好ま
しい。Examples of water-immiscible organic solvents include n-hexane and
Hydrocarbons having 6 to 10 carbon atoms such as i-hexane, n-heptane, i-heptane, octane, i-octane, cyclohexane, benzene, toluene, xylene or ethylbenzene; n-hexyl, 2-methylpentyl, 2- Alcohols having 6 to 10 carbon atoms such as ethylbutyl, s-hexyl, s-heptyl, n-octyl, 2-ethylhexyl, 2,6-dimethyl-4-heptyl, n-decyl alcohol; methyl-n-amyl ketone, methyl C7-8 ketones such as cyclohexanone or methylhexyl ketone; s-butyl acetate, i-butyl acetate, acetic acid-2
It is preferable to use esters having 6 to 8 carbon atoms such as ethylbutyl, s-amyl acetate or methyl amyl acetate, and halogenated hydrocarbons having 1 to 5 carbon atoms such as chloroform, dichloropentane or epichlorohydrin.
抽出方法は一般的な方法で実施すればよく、特に限定さ
れないが、その一例は次のとおりである。The extraction method may be a general method and is not particularly limited, but one example is as follows.
前記の形態の原料ミミズに対し、水性溶媒、濃度5〜70
(容量)%好ましくは10〜60(容量)%の有機溶媒の水
溶液、濃度80〜100(容量)%の水混和性有機溶媒、濃
度約100%の水非混和性有機溶媒から成る群から選ばれ
る少なくとも一種類の抽出剤を1〜100倍量(容量/重
量)好ましくは2〜30倍量用い、抽出温度は−40〜+60
℃、抽出接触時間は10分間から約100日間好ましくは30
分間から約40日間の間、時々又は連続撹拌したのち、静
置し、過して抽出液を分取した。過は加圧又は減圧
過器(機)又は遠心分離機を用いるとよい。抽出残渣
はよく洗浄したのち、抽出液と洗液とを合体する。抽出
液又は合液を60℃以下の温度で常圧、加圧又は減圧下で
濃縮、限外過濃縮又は凍結乾燥などの濃縮法で抽出溶
媒を除去して抽出物を得た。ただし、抽出剤として例え
ばエタノールを使用したときには、最終目的剤形の種類
により、完全に除去せずにエタノールを残留させること
もある。又、前記の抽出液又は合液の濃縮液の放置によ
る結晶析出法又は濃縮液に有機溶媒を添加して結晶を析
出せしめたのちに、過、乾燥して抽出物を得る方法も
用いられる。For the earthworms of the above-mentioned form, an aqueous solvent, a concentration of 5 to 70
(Volume)% preferably selected from the group consisting of an aqueous solution of an organic solvent having a concentration of 10 to 60 (volume)%, a water-miscible organic solvent having a concentration of 80 to 100 (volume)%, and a water-immiscible organic solvent having a concentration of about 100%. 1 to 100 times volume (volume / weight), preferably 2 to 30 times volume, of at least one extractant used, and the extraction temperature is -40 to +60.
℃, extraction contact time is 10 minutes to about 100 days, preferably 30
The mixture was allowed to stand for 4 minutes to about 40 days with occasional or continuous stirring, and the extract was collected by passing. It is preferable to use a pressure or pressure reducer (machine) or a centrifugal separator for the filtration. After thoroughly washing the extraction residue, the extraction liquid and the washing liquid are combined. The extract or the combined solution was concentrated at a temperature of 60 ° C. or lower under normal pressure, increased pressure or reduced pressure, and the extraction solvent was removed by a concentration method such as ultra-overconcentration or freeze-drying to obtain an extract. However, when, for example, ethanol is used as the extractant, ethanol may remain without being completely removed depending on the type of the final intended dosage form. Further, there is also used a crystal precipitation method in which the extract or the concentrated solution of the combined solution is allowed to stand, or a method in which an organic solvent is added to the concentrated solution to precipitate crystals, and then the extract is dried to obtain an extract.
上記の操作における原料ミミズに対する抽出液物の収率
は乾物換算で3〜60(重量)%である。この収率の相違
は、原料ミミズの形態、溶媒の種類、抽出温度、抽出時
間その他の抽出条件による。抽出温度が高いと、有効物
質が分解される危険があるので抽出温度は−40〜+60℃
が好ましい。The yield of the extracted liquid with respect to the raw earthworms in the above operation is 3 to 60 (weight)% in terms of dry matter. This difference in yield depends on the morphology of the raw material earthworm, the type of solvent, the extraction temperature, the extraction time and other extraction conditions. If the extraction temperature is high, the active substance may be decomposed, so the extraction temperature is -40 to + 60 ° C.
Is preferred.
抽出物中の含有成分は表−2及び表−3に示すように、
ミミズの乾燥粉末の成分と同じように18種のアミノ酸、
8種の金属などを含有する。特に、この抽出物中の蛋白
質は、原料ミミズと同じアミノ酸からなる蛋白質、糖質
蛋白質、金属結合蛋白質などを含有する。さらに抽出物
中には遊離アミノ酸、脂質、各種糖質、ATP及びATP様物
質その他の組成不明の有効な化学物質を含有する。The components contained in the extract are, as shown in Table 2 and Table 3,
18 amino acids, similar to the ingredients in earthworm dry powder
Contains 8 kinds of metals. In particular, the protein in this extract contains a protein consisting of the same amino acid as the starting earthworm, a glycoprotein, a metal-binding protein, and the like. Furthermore, the extract contains free amino acids, lipids, various sugars, ATP and ATP-like substances, and other effective chemical substances of unknown composition.
本発明において使用するミミズはアカミミズ(Lumbricu
s rubellus)、LTミミズ(別名ツリミミズ)(Lumbricu
s terrestris)、シマミミズ(Eisenia foetida)、カ
ッショクツリミミズ(Allolobophora caliginosa)、ム
ラサキツリミミズ(Dendrobaena octaedra)、サクラミ
ミズ(Allolobophora japonica Michaelsen)、ハッタ
ミミズ(Drawida hattamimizu Hatai)、セグロミミズ
(Pheretima divergens Michaelsen)、フツウミミズ
(Pheretima communissima)、ハタケミミズ(Pheretim
a agrestis)、シーボルトミミズ(Pheretima sieboldi
Horst)、ヒトツモンミミズ(Pheretima hilgendorf
i)、イソミミズ(Pontodrilus matsushimensis Iizuk
a)、イトミミズ(Tubifex hattai Nomura)、ゴトウイ
トミミズ(別名:ユリミミズ)〔Limnodrilus gotoi Ha
tai=L,socialis Stephenson〕などであり、通常生育
し、かつ有毒でないミミズならいずれのミミズでも利用
できる。The earthworms used in the present invention are red earthworms (Lumbricu
s rubellus), LT earthworm (aka Tsurumiwami) (Lumbricu
s terrestris), zebra earthworm (Eisenia foetida), brown earthworm (Allolobophora caliginosa), violet earthworm (Dendrobaena octaedra), sakura earthworm (Allolobophora japonica Michaelssen), hatta earthworm (Drawida hattamimizu hataidiver, groves). (Pheretima communissima), Hatakemimizu (Pheretim
a agrestis), Siebold earthworm (Pheretima sieboldi
Horst), Spotted Earthworm (Pheretima hilgendorf)
i), the earthworm (Pontodrilus matsushimensis Iizuk
a), Itomizu (Tubifex hattai Nomura), Goutouitomizu (aka Yurimizu) [Limnodrilus gotoi Ha
tai = L, socialis Stephenson], and any earthworm that normally grows and is not toxic can be used.
本発明のミミズ乾燥粉末及びミミズの抽出物を臨床治療
用として投与するときには、それの単独又は混合して用
いることもできる。その形態は経口剤又は非経口剤のい
ずれでもよいが、特に経口投与が好ましい。本発明品の
経口用の剤形としては、本発明品自体又は適宜な薬理的
に許容される医薬担体と混合してカプセル剤、錠剤、顆
粒剤、散在(粉剤)、コーテイング剤、糖衣錠、乳剤な
どの製剤が用いられる。医薬担体としては、例えば賦形
剤として乳糖、白糖、マニトール、ブトウ糖、デン粉、
ソルビトール、グリシン、リン酸カルシウム、微結晶セ
ルロースなど;結合剤としてデン粉、ゼラチン、アラビ
アゴム、ブドウ糖、白糖、ソルビトール、マニトール、
トラガント、ヒドロキシプロピルセルロース、ヒドロキ
シプロポキシメチルセルロース、カルボキシメチルセル
ロース、2−メチル−5−ビニルピリジン−メタアクリ
ル酸−アクリル酸メチルエチル共重合体、ポリビニルピ
ロリドン、アルギン酸ナトリウムなど;滑沢剤としてス
テアリン酸、硬化油、ステアリン酸マグネシウム、ステ
アリン酸カルシウム、ポリオキシエチレンモノステアレ
ート、タルク、酸化ケイ素、ポリエチレングリコールな
ど;崩壊剤としてバレイシヨデン粉、界面活性剤などを
含むデン粉;湿潤剤としてラウリル硫酸ナトリウムなど
があげられる。更に非経口的に投与する場合には坐剤と
して用いることができる。特に坐剤の基剤としてカカオ
脂、ウイテプソール(Witepsol)、サバナール(Subana
l)、ポリエチレングリコール、ポリプロピレングリコ
ール、グリセロゼラチン、ゼラチンカプセルなどが用い
られる。その他、メチルパラヒドロキシベンゾエート、
プロピルパラヒドロキシベンゾエート、ブチルパラヒド
ロキシベンゾエート、ブチルヒドキシアニソールなどの
公知の安全な防腐剤、その他の安全な色素を配合して用
いる。When the earthworm dry powder and earthworm extract of the present invention are administered for clinical treatment, they can be used alone or in combination. The form may be either oral or parenteral, but oral administration is particularly preferable. The oral dosage form of the product of the present invention includes capsules, tablets, granules, scattered (powder), coating agents, dragees, emulsions by mixing the product of the present invention itself or an appropriate pharmacologically acceptable pharmaceutical carrier. Formulations such as Examples of the pharmaceutical carrier include lactose, sucrose, mannitol, butter sugar, den powder as an excipient,
Sorbitol, glycine, calcium phosphate, microcrystalline cellulose, etc .; den powder, gelatin, gum arabic, glucose, sucrose, sorbitol, mannitol as a binder
Tragant, hydroxypropylcellulose, hydroxypropoxymethylcellulose, carboxymethylcellulose, 2-methyl-5-vinylpyridine-methacrylic acid-methylethyl acrylate copolymer, polyvinylpyrrolidone, sodium alginate, etc .; stearic acid as a lubricant, hardened oil , Magnesium stearate, calcium stearate, polyoxyethylene monostearate, talc, silicon oxide, polyethylene glycol and the like; disintegrants such as valesioden powder and den powder containing a surfactant; and wetting agents such as sodium lauryl sulfate. When administered parenterally, it can be used as a suppository. Especially as a base for suppositories, cocoa butter, Witepsol, Subana
l), polyethylene glycol, polypropylene glycol, glycerogelatin, gelatin capsules and the like are used. Others, methyl para hydroxy benzoate,
Known safe preservatives such as propylparahydroxybenzoate, butylparahydroxybenzoate, and butylhydroxyanisole, and other safe dyes are used in combination.
本発明の糖尿病治療剤のミミズ乾燥粉末及びミミズの抽
出物の投与量は、投与方法、患者の年齢、体重、状態及
び疾患の種類によつても変動するが、通常ヒトに一日当
り0.01gから5g程度が好ましい。最も好ましいのは一日
当り0.02gから2gで一日1〜3回に分けて投薬すること
である。The dose of the earthworm dry powder and earthworm extract of the therapeutic agent for diabetes of the present invention varies depending on the administration method, age, weight, condition of the patient and type of disease, but usually from 0.01 g per day to human. About 5 g is preferable. Most preferable is to administer 0.02 g to 2 g per day in 1 to 3 divided doses per day.
作用: 本発明のミミズ乾燥粉末の毒性及び糖尿病治療効果又は
血糖降下の薬理試験法とその結果について、以下、詳細
に説明する。Action: The toxicity of the earthworm dry powder of the present invention and the pharmacological test method for the therapeutic effect on diabetes or hypoglycemia and the result thereof will be described in detail below.
A.急性毒性試験: 体重30±2gのddy系雄マウス及び体重100±2gのウイスタ
ー(Wistar)系雄ラツト各一群5匹を用いて経口投与で
の急性毒性試験を行なつた。本発明のミミズ乾燥粉末M
−1(水分10.2%、灰分5.1%、窒素9.4%含有);同M
−2(水分10.4%、灰分5.3%、窒素8.6%含有);同M
−3(水分10.7%、灰分5.2%、窒素9.2%含有);同M
−4(水分10.6%、灰分5.6%、窒素9.6%含有);同M
−5(水分9.5%、灰分4.5%、窒素7.8%含有);同M
−6(水分9.2%、灰分4.7%、窒素8.4%含有)のそれ
ぞれの服用量を0.1g/Kgから8g/Kgに増加して前記のマウ
ス(0.1から5g/Kg)及びラツト(2から8g/Kg)に咽喉
さぐり棒で強制投与によつて個々に投薬した。試験期間
中動物は動物室温度22〜23℃に維持し、投薬後14日間観
察した。投薬された服容量での死亡は全く認められなか
つた。投薬後の中毒症及び行動を経時的に観察したが、
正常動物群と何等の相違は認められなかつた。又、体重
増加も正常動物群とほとんど差がなかつた。試験後に実
施した検視において主要器管のいかなる部分にも何等巨
視的障害は認められなかつた。従つて、本発明のミミズ
乾燥粉末は非常に低い毒性のためにLD50値を決定するこ
とができなかつた。A. Acute toxicity test: An acute toxicity test was carried out by oral administration using ddy male mice weighing 30 ± 2 g and Wistar male rats weighing 100 ± 2 g each in groups of five. Earthworm dry powder M of the present invention
-1 (water 10.2%, ash 5.1%, nitrogen 9.4%); Same as M
-2 (water content 10.4%, ash content 5.3%, nitrogen 8.6%); Same M
-3 (water content: 10.7%, ash content: 5.2%, nitrogen content: 9.2%);
-4 (water content: 10.6%, ash content: 5.6%, nitrogen content: 9.6%);
-5 (water content: 9.5%, ash content: 4.5%, nitrogen content: 7.8%);
Each dose of -6 (water 9.2%, ash 4.7%, nitrogen 8.4%) was increased from 0.1g / Kg to 8g / Kg, and the mouse (0.1 to 5g / Kg) and rat (2 to 8g) were added. / Kg) was individually dosed by gavage with a throat dragging rod. Animals were maintained at a room temperature of 22-23 ° C during the study period and observed for 14 days after dosing. No mortality was observed at the dosed dose. I observed toxicosis and behavior after administration over time,
No difference from the normal animal group was observed. Moreover, the weight gain was almost the same as that of the normal group. No macroscopic damage was observed in any part of the main organ in the autopsy performed after the test. Therefore, the earthworm dry powder of the present invention could not determine the LD50 value due to its very low toxicity.
B.実験的糖尿病マウスに対する作用 1.動物:体重30±2gのddy系雄性マウス1群5匹を用い
た。B. Effect on Experimental Diabetic Mice 1. Animals: One group of 5 male ddy mice each weighing 30 ± 2 g was used.
2.飼料及び飼育条件:日本クレア社製固型飼料を用い、
1ケージにマウス一匹を入れ、飼料及び水は自由摂取と
した。温度23±1℃及び湿度55±5%の恒温恒湿で飼育
した。2. Feed and breeding conditions: using solid feed manufactured by CLEA Japan,
One mouse was placed in one cage, and food and water were freely available. The animals were kept at a constant temperature and humidity of 23 ± 1 ° C and a humidity of 55 ± 5%.
前記のddy系雄性マウスを16時間絶食後、アロキサン75m
g/Kgを静脈内に投与し、48時間後に、本発明のミミズ乾
燥粉末M−1(水分10.2%、灰分5.1%、窒素9.4%);
同M−2(水分10.4%、灰分5.3%、窒素8.6%);同M
−3(水分10.7%、灰分5.2%、窒素9.2%);同M−4
(水分10.6%、灰分5.6%、窒素9.6%);同M−5(水
分9.5%、灰分4.5%、窒素7.8%);同M−6(水分9.2
%、灰分4.7%、窒素8.4%)の6種(300mg/Kg)をそれ
ぞれ生理的食塩水にけん濁して経口投与し、150分後に
心臓から採血し、グルコースオキシダーゼ法により血中
糖量を測定した。After fasting male ddy mice for 16 hours, alloxan 75m
g / Kg was administered intravenously and 48 hours later, the earthworm dry powder M-1 of the present invention (water content 10.2%, ash content 5.1%, nitrogen 9.4%);
Same M-2 (water content 10.4%, ash content 5.3%, nitrogen 8.6%);
-3 (water 10.7%, ash 5.2%, nitrogen 9.2%); M-4
(Water content 10.6%, ash content 5.6%, nitrogen 9.6%); M-5 (water content 9.5%, ash content 4.5%, nitrogen 7.8%); M-6 (water content 9.2)
%, Ash 4.7%, nitrogen 8.4%) 6 kinds (300 mg / Kg) suspended in physiological saline orally and orally administered, and after 150 minutes, blood was collected from the heart and blood glucose was measured by glucose oxidase method. did.
測定結果は表−5に示した。本発明のミミズ乾燥粉末は
有意に血糖を降下することがわかつた。The measurement results are shown in Table-5. It has been found that the earthworm dry powder of the present invention significantly lowers blood glucose.
製法3 原料ミミズの調製: 生きミミズ(アカミミズ)10kgを、リンゴ酸と乳酸2:1
の混合酸を溶解したpH5.8の酸性水溶液20l中に温度10℃
で3時間放置し、消化管内の糞土を十分に排泄させた。
この生きミミズを水で良く洗浄して生きミミズの体表面
に付着している泥、糞などの汚物を洗い落したのち、ウ
ルトラホモミキサー(日本精機株式会社製)で湿式粉砕
し、ミミズの懸濁液9.3kgを得た。このミミズ懸濁液を
1.55kgずつに6等分し、それぞれをE−1,−2,−3,−4,
−5及び−6とする。 Manufacturing method 3 Preparation of raw earthworms: 10 kg of live earthworms (red earthworms), malic acid and lactic acid 2: 1
10 ℃ in 20 l of pH 5.8 acidic aqueous solution containing mixed acid
It was allowed to stand for 3 hours to allow the fecal soil in the digestive tract to be excreted sufficiently.
This live earthworm is thoroughly washed with water to remove dirt, feces, and other dirt attached to the body surface of the live earthworm, and then wet pulverized with an ultra homo mixer (manufactured by Nippon Seiki Co., Ltd.) to suspend the earthworm. A suspension of 9.3 kg was obtained. This earthworm suspension
Divide into 1.55kg and divide into 6 equal parts, E-1, -2, -3, -4,
-5 and -6.
前記で得たE−1とE−2のミミズの懸濁液1.55kgを各
々のトレーに入れ−40℃で30時間凍結する。次に品温を
−40℃で0.1mmHgの真空下で6時間凍結乾燥し、次に25
℃で0.1mmHgの真空下で8時間乾燥したのち、次に45℃
で0.1mmHgの真空下で12時間乾燥し、最後に80℃で0.1mH
gの真空下で6時間乾燥することにより、2個のトレー
の各々にミミズの乾燥物318gを得た。これをK−1及び
K−2とする。1.55 kg of the E-1 and E-2 earthworm suspensions obtained above are placed in each tray and frozen at -40 ° C for 30 hours. Then, freeze-dry at -40 ℃ under vacuum of 0.1mmHg for 6 hours, then 25
After drying under vacuum of 0.1mmHg at ℃ for 8 hours, then at 45 ℃
Dried under vacuum of 0.1mmHg for 12 hours and finally 0.1mH at 80 ℃
Drying under g vacuum for 6 hours yielded 318 g of dried earthworm in each of two trays. These are designated as K-1 and K-2.
抽出物の調製: X−.ミミズの乾燥物(K−1)315gに5倍量の99%
メタノール1.575lを加え25℃で3回抽出したのち、最後
に残渣を3倍量の99%メタノール0.945lで洗浄し、抽出
液と洗液の合液を30℃で減圧濃縮乾固し、次に真空乾燥
することにより88.2gの粉末抽出物を得た。これを抽出
物X−とする。Preparation of extract: X-. 5% of 99% of dried earthworm (K-1) 315g
After adding 1.575 l of methanol and extracting 3 times at 25 ° C, the residue was washed with 0.945l of 99% methanol 3 times, and the combined extract and washings were concentrated to dryness at 30 ° C under reduced pressure. After vacuum drying, 88.2 g of powder extract was obtained. This is designated as Extract X-.
X−.ミミズの乾燥物(K−2)315gに、3倍量のク
ロロホルム0.945lと2倍量のエタノール0.63lの合液を
加え、20℃で3回抽出したのち、最後に残渣を2倍量の
エタノール0.63lで洗浄し、抽出液と洗液の合液を30℃
で減圧下濃縮乾固し、次に真空乾燥することにより72.5
gの粉末抽出物を得た。これを抽出物X−とする。X-. To 315 g of dried earthworm (K-2), a mixture of 3 volumes of 0.945 l of chloroform and 2 volumes of 0.63 l of ethanol was added, and the mixture was extracted 3 times at 20 ° C. Wash with 0.63 l of ethanol, and combine the extract and wash at 30 ° C.
Concentrate to dryness under reduced pressure at 72.5% by vacuum drying.
g powder extract was obtained. This is designated as Extract X-.
X−.ミミズの懸濁液(E−3)1.55kgに真水6.2lを
加えて10℃で2時間かきまぜたのち、過し、抽出液と
残渣に分取する。残渣を水洗したのち抽出液と洗液との
合液7.7lを得た。この合液7.7lにn−ヘキサン2.3lを
加えてかきまぜたのち、静置し、水溶部層とn−ヘキサ
ン層に分離後、水溶部層を分取し、30℃で減圧濃縮乾固
したのち、凍結乾燥し、粉末抽出物86.8gを得た。これ
を抽出物X−とする。X-. To 1.55 kg of the earthworm suspension (E-3), 6.2 l of fresh water is added, and the mixture is stirred at 10 ° C. for 2 hours, then passed and separated into an extract and a residue. After the residue was washed with water, 7.7 l of a combined liquid of the extract and the wash was obtained. After adding 2.3 liters of n-hexane to 7.7 liters of this combined liquid and stirring, the mixture was allowed to stand and separated into a water-soluble part layer and an n-hexane layer. The water-soluble part layer was separated and concentrated to dryness under reduced pressure at 30 ° C. Then, it was freeze-dried to obtain 86.8 g of a powder extract. This is designated as Extract X-.
X−.ミミズの懸濁液(E−4)1.55kgに40%エタノ
ール水溶液10lを加え、40℃で12時間かきまぜたのち、
過し、抽出液と残渣に分取する。残渣は40%エタノー
ル0.3lで洗浄したのち抽出液と洗液との合液を40℃で減
圧濃縮乾固したのち、真空乾燥し、粉末の抽出物69.7g
を得た。これを抽出物X−とする。X-. To 1.55 kg of the earthworm suspension (E-4), 10 l of 40% aqueous ethanol solution was added, and after stirring at 40 ° C for 12 hours,
And separate the extract and residue. The residue was washed with 0.3 l of 40% ethanol, and the combined extract and washing solution was concentrated to dryness under reduced pressure at 40 ° C and then vacuum dried to give 69.7 g of powdered extract.
Got This is designated as Extract X-.
X−.ミミズの懸濁液(E−5)1.55kgにpH6.4のリ
ン酸緩衝液2.5lを加えて、37℃で8時間インキュベーシ
ョンし、ミミズ体内に元来から含有するプロテアーゼの
作用を促進させたのち、過し、残渣をpH6.4のリン酸
緩衝液で洗浄し、抽出液と洗浄液との合液3.9lを得た。
この合液にアジ化ナトリウム1gを加えて37℃で8時間イ
ンキュベーションしたのち、30℃で減圧濃縮し、得た濃
縮液に2倍量のエタノールを加えて沈澱物を過し、分
取した沈澱を真空乾燥し、次に凍結乾燥して粉末の抽出
物64.2gを得た。これを抽出物X−とする。X-. 2.5 l of pH 6.4 phosphate buffer was added to 1.55 kg of the earthworm suspension (E-5) and incubated at 37 ° C. for 8 hours to accelerate the action of the protease originally contained in the earthworm body. After that, the residue was washed with a phosphate buffer of pH 6.4 to obtain 3.9 l of a combined solution of the extract and the wash.
After adding 1 g of sodium azide to this combined solution and incubating at 37 ° C. for 8 hours, the mixture was concentrated under reduced pressure at 30 ° C., and the obtained concentrated liquid was added with twice the amount of ethanol, and the precipitate was collected by filtration. Was dried in vacuum and then freeze-dried to obtain 64.2 g of powdery extract. This is designated as Extract X-.
X−.ミミズの懸濁液(E−6)1.55kgを天日で自然
乾燥したのち、粉末化したミミズの乾燥粉末(K−3と
する。)にエタノールとエチルエーテル2:1の混合溶媒9
00mlを加え、20℃で3回抽出た。最後に、残渣を前記の
混合溶媒で洗浄し、抽出液と洗液の合液を30℃で減圧下
濃縮乾固し、次に真空乾燥することにより61.5gび抽出
物を得た。これを抽出物X−とする。X-. 1.55 kg of the earthworm suspension (E-6) was naturally dried in the sun, and then dried earthworm powder (K-3) was mixed with ethanol and ethyl ether 2: 1 mixed solvent 9
00 ml was added, and the mixture was extracted 3 times at 20 ° C. Finally, the residue was washed with the above mixed solvent, and the combined solution of the extract and the wash was concentrated to dryness at 30 ° C. under reduced pressure, and then vacuum dried to obtain 61.5 g of an extract. This is designated as Extract X-.
製法4 泥がついている養殖生きミミズ(アカミミズ)13kgを水
で良く洗浄し、体表面に付着している泥を洗い落したの
ち、リンゴ酸とクエン酸の1:1の混合酸を溶存するpH6.2
の酸性水溶液40l中に温度8℃で3時間放置し、消化管
内の糞土を十分に排泄させたのち、生きミミズを水でよ
く洗浄して生きミミズの体表面に付着している泥、糞な
どの汚物を洗い落したのち生きミミズをミキサーにかけ
て湿式粉砕し、ミミズの懸濁液9.0kgを得た。このミミ
ズ懸濁液を1.5kgずつに6等分し、それをE−7,−8,−
9,−10,−11及び−12とする。Production method 4 13 kg of cultured live earthworms (red earthworms) with mud are thoroughly washed with water to wash off the mud adhering to the body surface, and then a 1: 1 mixed acid of malic acid and citric acid is dissolved in pH 6 .2
After leaving it in 40 liters of the acidic aqueous solution for 3 hours at a temperature of 8 ° C to excrete the fecal soil in the digestive tract sufficiently, the live earthworms are thoroughly washed with water and the mud and feces attached to the body surface of the live earthworms. After the dirt was washed off, live earthworms were wet-milled with a mixer to obtain 9.0 kg of earthworm suspension. This earthworm suspension was divided into 6 equal parts of 1.5 kg each, and they were divided into E-7, -8,-
They are 9, -10, -11 and -12.
前記で得たE−7とE−8のミミズ懸濁液1.5kgを各々
のトレーに入れ−30℃で40時間凍結したのち、次に品温
−40℃で0.1mmHgの真空下6時間凍結乾燥し、次にトレ
ーの乗せている棚温を30℃に上げ0.1mmHgの真空下6時
間乾燥したのち、棚温を50℃に上げ0.2mmHgの真空下で
8時間真空乾燥し、最後に棚温を78℃に上げ0.2mmHgの
真空下で8時間乾燥することによりミミズの各々の乾燥
物305gずつを得た。これをK−7とK−8とする。1.5 kg of the E-7 and E-8 earthworm suspensions obtained above were placed in each tray and frozen at -30 ° C for 40 hours, and then frozen at -40 ° C under a vacuum of 0.1 mmHg for 6 hours. Dry, then raise the temperature of the tray on which it is placed to 30 ° C and dry under vacuum of 0.1mmHg for 6 hours, then raise the temperature of rack to 50 ° C and vacuum dry under vacuum of 0.2mmHg for 8 hours, and finally to the shelf. The temperature was raised to 78 ° C. and dried under a vacuum of 0.2 mmHg for 8 hours to obtain 305 g of each dried product of earthworm. This is designated as K-7 and K-8.
抽出物の調製: X−.ミミズの乾燥物(K−7)300gに、3lの0.02%
パラヒドロキシ安息香酸エチルエステルを含む0.9%塩
化ナトリウム水溶液を加え、30℃で96時間かきまぜたの
ち、過し、残渣を0.9lの0.9%塩化ナトリウム水溶液
で洗浄し、抽出液と洗浄液とを合わせた清澄抽出液3.8l
を得た。これを限外過法で濃縮し、液量を0.16lと
し、これにエタノール0.16lを加えて沈澱分別したのち
の液に終濃度としてエタノール濃度が80%になるよう
に添加して得た沈澱を真空乾燥し、結晶粉末14.4gを得
た。これを抽出物X−−1とする。Preparation of extract: X-. To 300 g of dried earthworm (K-7), 0.02% of 3 l
0.9% Sodium chloride aqueous solution containing para-hydroxybenzoic acid ethyl ester was added, and the mixture was stirred at 30 ° C. for 96 hours and then passed through, the residue was washed with 0.9 l of 0.9% sodium chloride aqueous solution, and the extract and the washing solution were combined. 3.8 l of clear extract
Got This was concentrated by the ultrafiltration method to a liquid volume of 0.16 l, and 0.16 l of ethanol was added to this to separate the precipitate, which was then added to the liquid to a final concentration of 80% ethanol. Was vacuum dried to obtain 14.4 g of crystal powder. This is designated as Extract X-1.
抽出物X−−1の液を30℃で減圧濃縮乾固すること
により72.5gの結晶粉末を得た。これを抽出物X−−
2とする。The liquid of Extract X-1 was concentrated under reduced pressure to dryness at 30 ° C. to obtain 72.5 g of crystalline powder. This is the extract X--
Set to 2.
X−.ミミズの乾燥物(K−8)300gに、3lの0.1%
安息香酸ナトリウムを含む真水を添加し、32℃で72時間
かきまぜ抽出したのち、過し、残渣を0.6lの真水で洗
浄し、抽出液と洗浄液とを合わせた清澄抽出液3.5lを得
た。この抽出液を限外過法で濃縮した液を、次の減圧
濃縮乾固することにより69gの結晶粉末を得た。これを
抽出物X−とする。X-. To 300 g of dried earthworm (K-8), 0.1% of 3 l
Fresh water containing sodium benzoate was added, and the mixture was stirred and extracted at 32 ° C. for 72 hours, and then extracted, and the residue was washed with 0.6 l of fresh water to obtain 3.5 l of a clear extract containing the extract and the washing solution. The extract was concentrated by an ultrafiltration method and concentrated under reduced pressure to dryness to give 69 g of crystalline powder. This is designated as Extract X-.
X−.ミミズの懸濁液(E−9)1.5kgを40℃で真空
乾燥し、粉末化したミミズの乾燥粉末(K−9とす
る。)に、3lの0.02%のパラヒドロキシ安息香酸エチル
エステルを含む蒸留水を加え、32℃で120時間かきまぜ
たのち、過し、抽出液と残渣に分取する。残渣を蒸留
水でよく洗浄したのち、抽出液と洗浄液との合液を30℃
約1/10量に減圧濃縮したのち、4倍量のエタノールを加
え、よくかきまぜたのち、一昼夜静置し、生成した沈澱
を過し、エタノールで洗浄したのち、真空乾燥し粉末
抽出物72.5gを得た。これを抽出物X−とする。X-. 1.5 kg of the earthworm suspension (E-9) was vacuum dried at 40 ° C., and 3 L of 0.02% para-hydroxybenzoic acid ethyl ester was added to powdered earthworm dry powder (K-9). Distilled water is added, and the mixture is stirred at 32 ° C for 120 hours, passed, and separated into an extract and a residue. Thoroughly wash the residue with distilled water, and then combine the extract and washing solution at 30 ° C.
After concentrating under reduced pressure to about 1/10 volume, adding 4 volumes of ethanol, stirring well, allowing to stand for a whole day and night, filtering the formed precipitate, washing with ethanol, vacuum drying, and powder extract 72.5 g Got This is designated as Extract X-.
X−.ミミズの懸濁液(E−10)1.5kgに60%エタノ
ール水溶液7.5lを加え、密栓状態で時々かきまぜながら
20〜22℃で8日間静置した。X-. To 1.5 kg of the earthworm suspension (E-10), add 7.5 l of 60% aqueous ethanol solution, stirring occasionally with a tight stopper.
It was allowed to stand at 20-22 ° C for 8 days.
その後、過し、残渣を50%エタノール水溶液0.5lで洗
浄し、抽出液と洗浄液との合液を30℃で減圧濃縮乾固し
たのち凍結乾燥し、粉末抽出物40.5gを得た。これを抽
出物X−とする。Then, the residue was washed with 0.5 l of a 50% aqueous ethanol solution, and the combined solution of the extract and the wash was concentrated to dryness under reduced pressure at 30 ° C. and freeze-dried to obtain 40.5 g of a powder extract. This is designated as Extract X-.
X−.ミミズの懸濁液(E−11)1.5kgに50%エタノ
ール水溶液4.5lと50%イソプロパノール水溶液3lの混合
溶媒を加え、密栓状態で時々かきまぜながら8℃で16日
間静置した。X-. A mixed solvent of 4.5 l of a 50% aqueous ethanol solution and 3 l of a 50% isopropanol aqueous solution was added to 1.5 kg of the earthworm suspension (E-11), and the mixture was allowed to stand still at 8 ° C for 16 days while occasionally stirring with a stopper.
その後、過し、残渣を50%エタノール水溶液0.5lで洗
浄し、抽出液と洗浄液との合液を35℃で減圧濃縮乾固し
たのち凍結乾燥し、粉末抽出物28.2gを得た。これを抽
出物X−とする。Then, the residue was washed with 0.5 l of a 50% aqueous ethanol solution, and the combined solution of the extract and the wash solution was concentrated to dryness under reduced pressure at 35 ° C. and freeze-dried to obtain 28.2 g of a powder extract. This is designated as Extract X-.
X−.ミミズの懸濁液(E−12)1.5kgに60%エタノ
ール水溶液7.5lを加え、25℃で2時間かきまぜながら3
回抽出し、最後に残渣を60%エタノール水溶液1で洗
浄し、抽出液と洗液の合液を30℃で減圧濃縮乾固し、次
に凍結乾燥することにより90.5gの粉末抽出物を得た。
これを抽出物X−とする。X-. To 1.5 kg of the earthworm suspension (E-12), add 7.5 l of a 60% aqueous ethanol solution, and stir at 25 ° C for 2 hours to mix 3
It was extracted twice, and finally the residue was washed with 60% aqueous ethanol solution 1 and the combined extract and washings were concentrated to dryness under reduced pressure at 30 ° C and then freeze-dried to obtain 90.5 g of a powder extract. It was
This is designated as Extract X-.
本発明のミミズの抽出物、すなわち、原料ミミズを水性
溶媒、水混和性有機溶媒及び水非混和性有機溶媒からな
る群から選ばれる少なくとも一種類の抽出剤によって抽
出処理し、得られた抽出物の毒性及び血糖低下活性の薬
理試験法とその結果は次のとおりである。Earthworm extract of the present invention, i.e., the raw earthworm is subjected to extraction treatment with at least one extractant selected from the group consisting of an aqueous solvent, a water-miscible organic solvent and a water-immiscible organic solvent, to obtain an extract The pharmacological test method for the toxicity and blood glucose lowering activity and the results are as follows.
A−1.急性毒性試験: 前記Aの急性毒性試験法と同じ方法により測定した。す
なわち、体重30±2gのddy系雄マウス各一群5匹を用い
て経口投与での急性毒性試験をおこなった。A-1. Acute toxicity test: Measured by the same method as the acute toxicity test method of A above. That is, an acute toxicity test by oral administration was carried out using 5 groups of male ddy mice each weighing 30 ± 2 g.
例えば、前記の本発明のミミズの抽出物X−,−,
−,−,−,−,−及び−の8種類を用い
て、前記のマウスに0.1g/kgから5g/kgにに増加して、咽
喉さぐり棒で強制投与によって個々に投薬した。For example, the above-described earthworm extract X-,-,
Eight types of −, −, −, −, −, and − were used to increase the dose from 0.1 g / kg to 5 g / kg, and the mice were individually dosed by gavage with a throat drag pin.
試験中マウスは動物室温度22〜23℃に維持し、投薬後14
日間観察した。投薬された服用量での死亡は全く認めら
れなかった。かつ中毒症状の所見または剖検では異常は
全く認められなかった。従って、本発明のミミズからの
水性溶媒及び/又は有機溶媒による抽出物は非常に低い
毒性のためにLD50値を決定することができなかった。Mice were maintained at a room temperature of 22-23 ° C during the study and 14
Observed for a day. No mortality was observed at the doses administered. Moreover, no abnormalities were found in the findings of poisoning or autopsy. Therefore, the extract with the aqueous and / or organic solvent from the earthworms of the present invention could not determine the LD 50 value due to its very low toxicity.
B−1.実験的糖尿病マウスに対する作用 薬理試験: 前記Bの実験的糖尿病マウスに対する作用の薬理試験と
同じ方法により測定した。すなち、 1.動物:体重30±2gのddy系雄性マウス各1群5匹を用
いた。B-1. Effect on experimental diabetic mouse Pharmacological test: The effect on experimental diabetic mouse of B was measured by the same method as in the pharmacological test. That is, 1. Animals: 5 male ddy mice each weighing 30 ± 2 g were used.
2.飼料及び飼育条件:日本クレア社製固型飼料を用い、
1ケージにマウス1匹を入れ、飼料及び水は自由摂取と
した。温度23±1℃及び湿度55±5%の恒温恒湿で飼育
した。前記のddy系雄マウスを16時間絶食後、アロキサ
ン75mg/kgを静脈内に投与し、48時間後に、本発明のミ
ミズ乾燥粉末の4種〔K−1,−3,−7及び−9〕を300m
g/kg、又、本発明のミミズからの抽出物の9種〔X−
,−,−,−,−,−,−,−及び−
〕の50mg/kgをそれぞれ生理的食塩水に懸濁して経口
投与し、150分後に心臓から採血し、グルコースオキシ
ダーゼ法により血中糖量を測定した。2. Feed and breeding conditions: using solid feed manufactured by CLEA Japan,
One mouse was placed in one cage, and food and water were freely available. The animals were kept at a constant temperature and humidity of 23 ± 1 ° C and a humidity of 55 ± 5%. The ddy male mouse was fasted for 16 hours, and 75 mg / kg of alloxan was intravenously administered, and 48 hours later, 4 kinds of the earthworm dry powder of the present invention [K-1, -3, -7 and -9]. To 300m
g / kg, or 9 kinds of earthworm extract of the present invention [X-
,-,-,-,-,-,-,-And-
50 mg / kg of each of the above] was orally suspended in physiological saline, and after 150 minutes, blood was collected from the heart and the blood sugar amount was measured by the glucose oxidase method.
測定結果は表−5−1に示した。本発明のミミズの乾燥
粉末及びミミズの抽出物は有意に血糖を低下することが
わかった。ミミズの抽出物は、ミミズの乾燥粉末の1/6
の量でミミズの乾燥粉末よりも血糖値の低下率が大であ
った。The measurement results are shown in Table-5-1. The earthworm dry powder and earthworm extract of the present invention were found to significantly lower blood glucose. Earthworm extract is 1/6 of earthworm dry powder
The rate of decrease in blood sugar level was higher than that of dry earthworm powder.
C.ミミズ乾燥粉末のヒトに対する経口投与実験: 本実験に賛同を得た5人のボランテイア(Volunteer)
に食事療法と共に、後述の実施例6で製造したカプセル
剤C〔1カプセル剤にミミズ乾燥粉末(前記のM−3、
水分10.7%、灰分5.2%、窒素9.2%)150mg含有〕を1
回1カプセル剤1日3回を食後30分以内に経口服用とし
た。採血は62才の男性のみ投与1ケ月経過毎に行ない、
9ケ月間投薬し、採血した。59才の男性は投薬前と投薬
2、3、4ケ月後に採血した。76才の女性は投薬前と投
薬4ケ月後に採血し、79才の女性は投薬前と投薬3及び
6ケ月後に採血した。61才の女性は投薬前と投薬1、
3、4及び8ケ月後に採血を行なつた。血中糖量はグル
コールオキシダーゼ法により測定した。この結果は表−
6に示した。 C. Oral Administration of Earthworm Dry Powder to Humans: Volunteer of 5 people who agreed with this experiment
A capsule C prepared in Example 6 to be described later along with diet was added to 1 capsule of earthworm dry powder (M-3,
Water 10.7%, ash 5.2%, nitrogen 9.2%) 150mg]] 1
1 capsule 3 times a day was taken orally within 30 minutes after eating. Blood collection is performed only for a 62-year-old man every month after administration.
The drug was administered for 9 months and blood was collected. A 59-year-old man took blood before and 2, 3, and 4 months after the administration. A 76-year-old woman collected blood before and 4 months after the administration, and a 79-year-old woman collected blood before and 3 and 6 months after the administration. The 61-year-old woman is before and 1
Blood was collected after 3, 4 and 8 months. The blood sugar level was measured by the glucose oxidase method. This result is
6 shows.
この実験を行なつた地方住民健康人の血糖の標準値(mg
/dl)は朝食前50〜100、朝食2時間後150以下、昼食前5
0〜100、昼食2時間後150以下、夕食前50〜100、夕食2
時間後150以下である。表−6に示した5人のボランテ
イアとも、薬物投与前の朝食前の空腹時の血中糖量がい
ずれも高血糖値であり、糖尿病患者であつた。 The standard value of blood glucose (mg in healthy people of local people who carried out this experiment)
/ dl) 50 to 100 before breakfast, 150 hours or less after 2 hours, 5 before lunch
0 to 100, 2 hours after lunch, 150 or less, 50 to 100 before dinner, 2 dinners
Less than 150 hours later. All of the five volunteers shown in Table 6 had high blood sugar levels on the fasting state before the drug administration and before breakfast, and were diabetic patients.
中程度の糖尿病と考えられる62才の男性の場合は、本発
明のミミズ乾燥粉末投与2ケ月後から血中糖量の改善が
みられ、投与3ケ月後では6項目の検査値の内、外食2
時間後の1項目の値が185mg/dlと高い以外は、ほぼ標準
値近くまで改善された。投与4ケ月後は6項目の検査値
全部が標準値に達した。それ以後、5ケ月間の6項の血
中糖量は標準値の範囲内を保持した。In the case of a 62-year-old man who is considered to have moderate diabetes, the blood sugar level was improved from 2 months after the administration of the earthworm dry powder of the present invention, and after 3 months from the administration, eating out of 6 test values was performed. Two
It was improved to almost the standard value except that the value of one item after the time was as high as 185 mg / dl. After 4 months from the administration, all 6 test values reached the standard values. After that, the blood sugar level of the 6th item within the range of the standard value was maintained for 5 months.
59才の男性は、投薬3ケ月後に6項目の検査値の内、昼
食前の1項目の値が114mg/dlと僅かに高いほかは、標準
値に達し、投与4ケ月後には6項目すべて標準値の範囲
内に達した。A 59-year-old man reached the standard value except that the value of one item before lunch was slightly higher than 114 mg / dl out of the 6 items after 3 months of administration, and all 6 items were standard after 4 months of administration. Reached the value range.
79才の女性は投与3ケ月後で、6項目の検査値の内、昼
食2時間後と夕食前の値が171及び107mg/dlと僅かに高
い値である以外の4項目の値は、標準値の範囲内に改善
され、投与6ケ月後には完全に標準値に達した。A 79-year-old woman had 4 months 'standard values except 3 months after administration and 6 items' test values 2 hours after lunch and before dinner were slightly higher at 171 and 107 mg / dl. It improved within the range of values and completely reached the standard value 6 months after the administration.
76才の女性は軽度の糖尿病患者であつたが、投与4ケ月
後に6項目の血中糖量は標準値に達した。A 76-year-old woman was a mild diabetic patient, and the blood sugar levels in the 6 items reached the standard values 4 months after the administration.
61才の女性は、かなり重度の糖尿病患者である。この女
性に、本発明のミミズ乾燥粉末を投与した4ケ月後か
ら、血中糖量の改善が見られ、8ケ月後には朝食2時間
後と昼食前の値がそれぞれ197と210mg/dlと高い値であ
る以外の4項目は標準値に達した。The 61-year-old woman is a fairly severely diabetic. This woman showed an improvement in blood sugar level 4 months after the administration of the earthworm dry powder of the present invention. After 8 months, the values 2 hours after breakfast and before lunch were as high as 197 and 210 mg / dl, respectively. The four items other than the values reached the standard values.
このミミズ乾燥粉末のヒトへの経口投与実験は、安全
に、かつ、副作用は何等発生することなく、無事に終了
することができた。たとえば、6〜9ケ月間の長期投与
においても、標準下限値以下まで血中糖量値が低下する
低血糖発生の危険は一度もなく、本発明のミミズ乾燥粉
末は安全な薬剤であることがわかつた。The oral administration experiment of this dried earthworm powder to humans could be safely completed without any side effect. For example, even after long-term administration for 6 to 9 months, there is no risk of hypoglycemia in which the blood sugar level falls below the standard lower limit, and the earthworm dry powder of the present invention is a safe drug. Wakatsuta.
上記の結果を総括すると次のとおりである。すなわち、
ミミズ乾燥粉末の経口投与では、かなり重度の糖尿病患
者の場合、前記6項目全部の血中糖量値を標準値まで降
下させることは稍々困難であつたが、投与8ケ月後には
6項目中4項目の血中糖量を標準値まで降下させるなど
の改善効果のあることがわかつた。然し、軽・中程度の
糖尿病患者の場合には、投与4ケ月後以降から6項目全
部の血中糖量を標準値以内まで低下させることができ
た。本発明のミミズ乾燥粉末は安全ですぐれた血糖降下
剤、すぐれた糖尿病治療・予防剤であることがわかつ
た。The above results are summarized as follows. That is,
Oral administration of earthworm dry powder was difficult to lower the blood sugar levels of all the above 6 items to the standard value in the case of diabetic patients with severe severity. It was found that there was an improving effect such as reducing the blood sugar levels in the four items to the standard value. However, in the case of light / moderate diabetic patients, the blood sugar levels of all 6 items could be reduced to within the standard value from 4 months after administration. It has been found that the earthworm dry powder of the present invention is a safe and excellent hypoglycemic agent and an excellent therapeutic / preventive agent for diabetes.
上記の結果により、ミミズからの溶媒抽出物であるミミ
ズの抽出物もミミズ乾燥粉末と同じように、ヒトに対し
安全で、かつ、すぐれた血糖降下剤、すぐれた糖尿病・
予防剤であることが容易にわかった。すなわち、ミミズ
の抽出物とミミズの乾燥粉末とは製造法に僅少の相違は
あるが、同じ出発原料の生きミミズ又はなまミミズから
製造したものゆえ、当然の結果と考える。Based on the above results, earthworm extract, which is a solvent extract from earthworms, is safe for humans as well as earthworm dry powder, and is an excellent hypoglycemic agent, excellent diabetes
It was easily found to be a preventive agent. That is, although there is a slight difference in the production method between the earthworm extract and the earthworm dry powder, it is considered a natural result because they were produced from live earthworms or ground earthworms of the same starting material.
実施例1. 錠剤A ミミズの乾燥粉末 150mg (成分は前記M−3と同じ) マニトール 123 ヒドロキシプロポキシメチルセルロース 7 タ ル ク 5 微結晶セルロース 60 水素化ヒマシ油 5 計350mg 錠剤B ミミズの乾燥粉末 150mg (成分は前記M−3と同じ) トウモロコシデン粉 60 乳 糖 80 タ ル ク 7 ステアリン酸マグネシウム 3 計300mg 錠剤C ミミズの乾燥粉末 150mg (成分は前記M−3と同じ) 可溶性デン粉 20 トウモロコシデン粉 125 微結晶セルロース 45 酸化ケイ素 6 ステアリン酸マグネシウム 4 計350mg 上記処方に従い均一によく混合した粉末を打錠機によ
り、各種重量の錠剤を製造した。Example 1. Tablet A Earthworm dry powder 150 mg (the components are the same as M-3 above) Manitol 123 Hydroxypropoxymethylcellulose 7 Talc 5 Microcrystalline cellulose 60 Hydrogenated castor oil 5 total 350 mg Tablet B Earthworm dry powder 150 mg ( Ingredients are the same as M-3) Corn corn flour 60 Lactose 80 talc 7 Magnesium stearate 3 Total 300 mg Tablet C Earthworm dry powder 150 mg (Ingredients are the same as M-3) Soluble den flour 20 Corn den flour 125 Microcrystalline Cellulose 45 Silicon Oxide 6 Magnesium Stearate 4 Total 350 mg According to the above formulation, the powders that were uniformly and well mixed were manufactured into tablets of various weights using a tableting machine.
実施例2. 顆粒剤A ミミズの乾燥粉末 150mg (成分は前記M−2と同じ) 乳 糖 20 微結晶セルロース 60 トウモロコシデン粉 15 ヒドロキシプロピルセルロース 5 計250mg 上記処方に従い、流動層造粒装置を用い、ミミズの乾燥
粉末、乳糖、微結晶セルロース及びトウモロコシデン粉
をよく混合し、ヒドロキシプロピルセルロースの5%水
溶液を結合剤として噴霧し、低温乾燥後顆粒とした。Example 2. Granules A Dry powder of earthworm 150 mg (the components are the same as M-2) Lactose 20 Microcrystalline cellulose 60 Corn den powder 15 Hydroxypropyl cellulose 5 250 mg in total According to the above formulation, a fluidized bed granulator is used. , Earthworm dry powder, lactose, microcrystalline cellulose and corn den powder were mixed well and sprayed with a 5% aqueous solution of hydroxypropyl cellulose as a binder to obtain low temperature dried granules.
実施例3. 顆粒剤B ミミズの乾燥粉末 100mg (成分は前記M−2と同じ) マニトール 10 微結晶セルロース 85 カルボキシメチルセルロースカルシウム 2 ステアリン酸マグネシウム 1.5 硬 化 油 1.5 計200.0mg 顆粒剤C ミミズの乾燥粉末 150mg (成分は前記M−2と同じ) 乳 糖 53 トウモロコシデン粉 39 バレイシヨデン粉 2 タ ル ク 3 ステアリン酸マグネシウム 3 計250mg 上記処方に従い、よく混合した粉末を押出機で顆粒剤を
製造した。Example 3. Granules B Earthworm dry powder 100 mg (the components are the same as M-2 above) Manitol 10 Microcrystalline cellulose 85 Carboxymethylcellulose calcium 2 Magnesium stearate 1.5 Hardening oil 1.5 Total 200.0 mg Granules C Earthworm dry powder 150 mg (the components are the same as the above M-2) Lactose 53 Corn den powder 39 Valeshioden powder 2 Tark 3 Magnesium stearate 3 Total 250 mg According to the above prescription, the well mixed powder was manufactured into granules by an extruder.
実施例4. カプセル剤A ミミズの乾燥粉末 150mg (成分はM−2と同じ) 乳 糖 28 微結晶セルロース 47 マニトール 10 トウモロコシデン粉 10 ポリビニルピロリドン 2 ヒドロキシプロピルセルロース 3 計250mg 上記処方の内、ヒドロキシプロピルセルロース以外の成
分を流動層造粒装置を用いてよく混合したのち、ヒドロ
キシプロピルセルロースの5%水溶液を結合剤として噴
霧し、低温乾燥後顆粒とした。この顆粒を硬カプセルに
250mgずつ充填して硬カプセル剤を製造した。Example 4. Capsule A Dry powder of earthworm 150 mg (the components are the same as M-2) Lactose 28 Microcrystalline cellulose 47 Manitol 10 Corn den powder 10 Polyvinylpyrrolidone 2 Hydroxypropyl cellulose 3 250 mg in total In the above formulation, hydroxypropyl Components other than cellulose were well mixed using a fluidized bed granulator, and then a 5% aqueous solution of hydroxypropyl cellulose was sprayed as a binder, and dried at low temperature to give granules. These granules into hard capsules
A hard capsule was prepared by filling 250 mg each.
実施例5. カプセル剤B 実施例3により製造した顆粒剤Cを硬カプセルに、250m
gずつ充填して硬カプセル剤を製造した。Example 5. Capsule B Granules C prepared according to Example 3 are hard capsules, 250m
Each g was filled to prepare a hard capsule.
実施例6. カプセル剤C ミミズの乾燥粉末 150mg (成分は前記M−3と同じ) リン酸−水素カルシウム 60 リン酸−水素ナトリウム 10 マニトール 28 ステアリン酸マグネシウム 2 計250mg 上記処方したものをよく混合し、この混合粉末をNo.1の
ゼラチンカプセルに250mgずつ充填し、カプセル剤を製
造した。Example 6. Capsule C Earthworm dry powder 150 mg (the components are the same as M-3 above) Phosphoric acid-calcium hydrogen 60 Phosphoric acid-sodium hydrogen 10 Manitol 28 Magnesium stearate 2 total 250 mg Mix well with the above formulation. No. 1 gelatin capsules were filled with 250 mg each of this mixed powder to produce capsules.
実施例7. 腸溶錠剤 ミミズの乾燥粉末 100mg (成分は前記M−1と同じ) マニトール 10 微結晶セルロース 85 カルボキシメチルセルロースカルシウム 2 ステアリン酸マグネシウム 1.5 硬化油 1.5 計200mg 上記の処方に従い、均一に混合した粉末を打錠機にて素
錠を製造したのち、次に示す腸溶剤皮のコーテイング剤
でコーテイングし、腸溶錠剤を製造した。Example 7. Enteric coated tablet Earthworm dry powder 100 mg (the components are the same as M-1) Manitol 10 Microcrystalline cellulose 85 Carboxymethylcellulose calcium 2 Magnesium stearate 1.5 Hardened oil 1.5 Total 200 mg According to the above formulation, they were uniformly mixed. An uncoated tablet was produced from the powder with a tableting machine and then coated with the following enteric coating coating agent to produce an enteric coated tablet.
コーテイング剤 ヒドロキシプロピルメチルセルロースフタレート14.8mg ジオクチルフタレート 2.3 ステアリン酸 2.3 軽質酸化ケイ素 0.6 計20.0mg 実施例8. 散剤A ミミズの乾燥粉末 150mg (成分は前記M−4と同じ) マニトール 50 トウモロコシデン粉 50 計250mg 散剤B ミミズ乾燥粉末 150mg (成分は前記M−4と同じ) リン酸−水素カルシウム 20 トウモロコシデン粉 80 計250mg 上記成分をそれぞれ円錐混合機中で均一によく混合して
散剤とした。Coating agent Hydroxypropyl methyl cellulose phthalate 14.8 mg Dioctyl phthalate 2.3 Stearic acid 2.3 Light silicon oxide 0.6 Total 20.0 mg Example 8. Powder A Earthworm dry powder 150 mg (the same ingredients as M-4) Manitol 50 Corn den powder 50 Total 250 mg Powder B Earthworm dry powder 150 mg (the components are the same as M-4) Calcium phosphate-hydrogen hydrogen 20 Corn den powder 80 Total 250 mg The above components were uniformly and well mixed in a conical mixer to obtain a powder.
実施例9. 坐剤A ミミズの乾燥粉末 200mg (成分は前記M−5と同じ) ウイテツプソール 540 (Witepsol)E−85 ウイテツプソール 1,454 (〃)W−35 メチルパラヒドロキシベンゾエート 3 ブチルパラヒドロキシベンゾエート 3 計2,200mg 坐剤B ミミズの乾燥粉末 200mg (成分は前記M−6と同じ) ブチルヒドロキシアニソール 6 半合成グリセリド 2,900 計3,106mg 上記処方したものをそれぞれよく混合した熔融物をアル
ミニウム製の型に注入し、冷却して坐剤を製造した。Example 9. Suppository A Dry powder of earthworm 200 mg (the components are the same as M-5 above) Witepsol 540 (Witepsol) E-85 Witepsol 1,454 (〃) W-35 Methylparahydroxybenzoate 3 Butylparahydroxybenzoate 3 Total 2,200 mg Suppository B Earthworm dry powder 200 mg (the components are the same as M-6 above) Butylhydroxyanisole 6 Semi-synthetic glyceride 2,900 3,106 mg The melts in which the above-mentioned prescriptions are well mixed are poured into an aluminum mold, Upon cooling, suppositories were prepared.
実施例10. カプセル剤D ミミズ乾燥粉末 150mg (成分は前記M−2と同じ) ラウリル硫酸ナトリウム 4 リン酸−水素ナトリウム 1 マニトール 93 ステアリン酸マグネシウム 2 計250mg 上記処方したものをよく混合する。この混合粉末をNo.1
のゼラチンカプセルに250mgずつ充填し、カプセル剤を
製造した。Example 10. Capsule D Earthworm dry powder 150 mg (the components are the same as M-2) Sodium lauryl sulfate 4 Sodium phosphate-hydrogen hydrogen 1 Manitol 93 Magnesium stearate 2 Total 250 mg The above-prepared ingredients are well mixed. This mixed powder is No.1
Each 250 mg of each gelatin capsule was filled to prepare a capsule.
実施例11 カプセル剤 E ミミズの抽出物 30mg (前記X−) 乳 糖 28 微結晶セルロース 47 マニトール 100 トウモロコシデン粉 40 ポリビニルピロリドン 2 ヒドロキシプロピルセルロース 3 計250mg 上記処方の内、ヒドロキシプロピルセルロース以外の成
分を流動層造粒装置を用いてよく混合したのち、ヒドロ
キシプロピルセルロースの5%水溶液を結合剤として噴
霧し、40℃で乾燥後顆粒とした。この顆粒硬カプセルに
250mgずつ充填して硬カプセル剤を製造した。Example 11 Capsule E Earthworm extract 30 mg (X-) Lactose 28 Microcrystalline cellulose 47 Manitol 100 Corn den powder 40 Polyvinylpyrrolidone 2 Hydroxypropylcellulose 3 250 mg in total In the above formulation, components other than hydroxypropylcellulose were used. After mixing well using a fluidized bed granulator, a 5% aqueous solution of hydroxypropyl cellulose was sprayed as a binder and dried at 40 ° C. to give granules. In this granular hard capsule
A hard capsule was prepared by filling 250 mg each.
実施例12 カプセル剤 F 顆 粒 剤 ミミズの抽出物 30mg (前記X−) 乳 糖 103 トウモロコシデン粉 89 バレイショデン粉 22 タ ル ク 3 ステアリン酸マグネシウム 3 計250mg 上記処方に従い、よく混合した粉末を抽出機で顆粒剤を
製造した。この顆粒剤を硬カプセルに250mgずつ充填し
て硬カプセル剤を製造した。Example 12 Capsule F Condyle Granules Earthworm extract 30 mg (X-) Lactose 103 Corn den powder 89 Potato powder 22 Talc 3 Magnesium stearate 3 total 250 mg Extract well mixed powder according to the above formulation The granules were produced on the machine. Hard capsules were manufactured by filling 250 mg each of the granules into hard capsules.
実施例13 カプセル剤 G ミミズの抽出物 30mg (前記X−) リン酸−水素カルシウム 60 リン酸−水素ナトリウム 20 マニトール 38 ステアリン酸マグネシウム 2 計150mg 上記処方したものをよく混合し、この混合粉末をゼラチ
ンカプセルに150mgずつ充填し、カプセル剤を製造し
た。Example 13 Capsule G Earthworm extract 30 mg (X-) Phosphoric acid-calcium hydrogen 60 Phosphate-sodium hydrogen 20 Manitol 38 Magnesium stearate 2 total 150 mg The above-prepared mixture was mixed well and the mixed powder was gelatinized. Capsules were manufactured by filling 150 mg each into capsules.
実施例14カプセル剤 H ミミズ抽出物 30mg (前記X−) ラウリル硫酸ナトリウム 4 リン酸−水素ナトリウム 1 マニトール 113 ステアリン酸マグネシウム 2 計150mg 上記処方したものをよく混合する。この混合粉末をゼラ
チンカプセルに150mgずつ充填し、カプセル剤を製造し
た。Example 14 Capsule H Earthworm extract 30 mg (X-) Sodium lauryl sulfate 4 Sodium phosphate-hydrogen hydrogen 1 Manitol 113 Magnesium stearate 2 Total 150 mg The above-prepared ingredients are mixed well. A gelatin capsule was filled with each 150 mg of the mixed powder to produce a capsule.
実施例15 カプセル剤 I ミミズ乾燥粉末 75mg (前記M−2と同じ) ミミズ抽出物 15mg (前記のX−) ラウリル硫酸ナトリウム 4 リン酸−水素ナトリウム 1 マニトール 153 ステアリン酸マグネシウム 2 計250mg 上記処方したものをよく混合する。この混合粉末をゼラ
チンカプセルに250mgずつ充填し、カプセル剤を製造し
た。Example 15 Capsule I Earthworm dry powder 75 mg (same as M-2 above) Earthworm extract 15 mg (X- above) Sodium lauryl sulfate 4 Sodium phosphate-hydrogen 1 Manitol 153 Magnesium stearate 2 Total 250 mg Mix well. A gelatin capsule was filled with 250 mg of each of the mixed powders to manufacture capsules.
実施例16 カプセル剤 J ミミズ乾燥粉末 50mg (前記M−4と同じ) ミミズの抽出物 20mg (前記のX−) ラウリル硫酸ナトリウム 2 マニトール 176 ステアリン酸マグネシウム 2 計250mg 上記処方したものをよく混合する。この混合粉末をゼラ
チンカプセルに250mgずつ充填し、カプセル剤を製造し
た。Example 16 Capsule J Earthworm dry powder 50 mg (same as M-4 above) Earthworm extract 20 mg (X- above) Sodium lauryl sulfate 2 Manitol 176 Magnesium stearate 2 250 mg A mixture of the above formulations is mixed well. A gelatin capsule was filled with 250 mg of each of the mixed powders to manufacture capsules.
発明の効果: 上記に述べたように、本発明は、ミミズの乾燥粉末及び
ミミズの抽出物を有効成分とする糖尿病治療剤に関す
る。アロキサンによる実験的糖尿病マウスに、ミミズの
乾燥粉末及びミミズの抽出物を投与することにより、有
意に血中糖量を低下させることができた。EFFECTS OF THE INVENTION As described above, the present invention relates to a therapeutic agent for diabetes which comprises dry earthworm powder and earthworm extract as active ingredients. Administration of dry earthworm powder and earthworm extract to experimentally diabetic mice with alloxan was able to significantly reduce blood sugar levels.
次に、5人の糖尿病患者のボランテイアに、食事療法と
共にミミズ乾燥粉末カプセル剤(150mg含量)を1回1
剤1日3回食後経口で4〜9ケ月間投与した。投与1ケ
月、2ケ月又は3〜4ケ月後から少なくとも1ケ月経過
毎に、朝食前、朝食2時間後、昼食前、昼食2時間後、
夕食前、夕食2時間後の6回採血し、血中糖量を測定し
た。この結果、軽・中程度の糖尿病患者の場合、ミミズ
乾燥粉末投与2〜3ケ月後から改善され、投与4ケ月後
以降からは、前記6項目全部の血中糖量を標準値(朝・
昼・夕の3食前の血糖の標準値は50〜100mg/dl、同じ各
3食2時間後の血糖の標準値は150mg/dl以下)の範囲内
まで降下させることができた。重度の糖尿病患者の場
合、前記6項目全部の血糖を標準値の範囲内まで降下さ
せることは稍々困難であつたが、投与8ケ月後には6項
目中4項目の血糖を標準値まで降下させる改善効果を示
した。又、ミミズ乾燥粉末6〜9ケ月間の長期投与にお
いても、血糖が標準値の下限値以下まで降下した低血糖
発生の危険は皆無であつた、すなわち、動物実験及びヒ
トへの経口投与実験により、本発明のミミズの乾燥粉末
及びミミズの抽出物は、安全で、かつ、すぐれた糖尿病
治療・予防剤であることがわかつた。Next, 5 diabetic volunteers were given one meal of earthworm dry powder capsules (150mg content) once with diet.
The drug was orally administered three times a day after meals for 4 to 9 months. From 1 month, 2 months or 3 to 4 months after administration, at least every 1 month, before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch,
Blood was collected 6 times before and 2 hours after dinner to measure the blood sugar level. As a result, in the case of mild to moderate diabetic patients, it was improved from 2 to 3 months after the administration of the earthworm dry powder, and from 4 months after the administration, the blood sugar levels of all the above 6 items were the standard values (morning
The standard value of blood glucose before three meals during the day and evening was 50 to 100 mg / dl, and the standard value of blood glucose two hours after the same meal was 150 mg / dl or less). In the case of severe diabetic patients, it has been difficult to lower the blood glucose levels of all 6 items to within the standard range, but after 8 months from the administration, the blood glucose levels of 4 items out of 6 items are lowered to the standard value. The improvement effect was shown. In addition, even after long-term administration of the earthworm dry powder for 6 to 9 months, there was no risk of hypoglycemia in which blood glucose dropped below the lower limit of the standard value, that is, by animal experiments and oral administration experiments to humans. It has been found that the dry powder of earthworm and the extract of earthworm of the present invention are safe and excellent agents for treating and / or preventing diabetes.
Claims (12)
糖尿病治療剤。1. A therapeutic agent for diabetes containing earthworm dry powder as an active ingredient.
リウム塩、無機酸ナトリウム塩、有機酸カリウム塩及び
無機酸カリウム塩から成る群から選ばれた少なくとも1
種類の化合物を0.3(重量)%以下含有する水溶液中又
は真水中に放置して生きミミズの消化管内の糞土をはか
せたのち、生きミミズの体表面に付着する汚物を水で洗
浄除去して、湿式粉砕をおこなうか、又は生きミミズの
体表面に付着する汚物を水で洗浄除去したのちの生きミ
ミズを前記水溶液中又は真水中に放置して生きミミズの
消化管内の糞土をはかせたのち、湿式粉砕をおこない、
得た懸濁液を−10〜−60℃で凍結したのち、−60〜80℃
の範囲内で温度を階段的に上げながら10mmHg以下の真空
度で10〜100時間凍結・真空乾燥をおこない、この内、
最終工程の真空乾燥を70〜80℃で0.01〜0.5mmHgの真空
下で5〜10時間乾燥することを特徴とするミミズ乾燥粉
末を有効成分として含有する糖尿病治療剤。2. Live earthworm is at least one selected from the group consisting of organic acid, inorganic acid, organic acid sodium salt, inorganic acid sodium salt, organic acid potassium salt and inorganic acid potassium salt.
After standing in an aqueous solution containing 0.3 (wt)% or less of various kinds of compounds or in fresh water to cover the excrement in the digestive tract of live earthworms, wash and remove the dirt attached to the body surface of live earthworms with water, After performing wet pulverization or washing and removing the dirt attached to the body surface of live earthworms with water, the live earthworms are left in the aqueous solution or in fresh water to spread the excrement in the digestive tract of the live earthworms, and then wet. Crush,
Freeze the obtained suspension at -10 to -60 ℃, then -60 to 80 ℃
Freeze and vacuum dry for 10 to 100 hours at a vacuum degree of 10 mmHg or less while raising the temperature stepwise within the range of
An antidiabetic agent containing an earthworm dry powder as an active ingredient, which is characterized in that vacuum drying in the final step is dried at 70 to 80 ° C. under a vacuum of 0.01 to 0.5 mmHg for 5 to 10 hours.
置して生きミミズの消化管内の糞土をはかせたのち、生
きミミズの体表面に付着する汚物を水で洗浄除去し、次
に湿式粉砕以降の前記工程をおこなう特許請求の範囲第
2項記載の糖尿病治療剤。3. The live earthworm is left in the aqueous solution or in fresh water to cover the excrement in the digestive tract of the live earthworm, and then the dirt attached to the body surface of the live earthworm is washed and removed with water, and then wet grinding. The antidiabetic agent according to claim 2, wherein the subsequent steps are performed.
生きミミズが汚物の一部を水で洗浄した生きミミズであ
る特許請求の範囲第3項記載の糖尿病治療剤。4. The therapeutic agent for diabetes according to claim 3, wherein the live earthworm before being left in the aqueous solution or in fresh water is a live earthworm in which a part of the waste is washed with water.
洗浄除去したのち、生きミミズを前記水溶液又は真水中
に放置して生きミミズの消化管内の糞土をはかせ、次に
湿式粉砕以降の前記工程をおこなう特許請求の範囲第2
項記載の糖尿病治療剤。5. After cleaning and removing the dirt attached to the body surface of live earthworms with water, the live earthworms are allowed to stand in the above-mentioned aqueous solution or fresh water to cover the excrement in the digestive tract of the live earthworms, and then wet grinding Claim 2 which performs the said process
The therapeutic agent for diabetes according to the item.
洗浄除去したのち、生きミミズを前記水溶液又は真水中
に放置して生きミミズの消化管内の糞土をはかせ、さら
に水で洗浄したのち、次に湿式粉砕以降の前記工程をお
こなう特許請求の範囲第5項記載の糖尿病治療剤。6. After washing away the dirt attached to the body surface of the live earthworm with water, the live earthworm is left in the aqueous solution or fresh water to spread the excrement in the digestive tract of the live earthworm, and then wash with water. The diabetes treatment agent according to claim 5, further comprising the step of wet pulverization and subsequent steps.
ゴ酸、酒石酸又は乳酸である特許請求の範囲第2,3,4,5
又は6項記載の糖尿病治療剤。7. An organic acid is acetic acid, citric acid, succinic acid, malic acid, tartaric acid or lactic acid.
Or a therapeutic agent for diabetes according to item 6.
請求の範囲第2,3,4,5又は6項記載の糖尿病治療剤。8. The therapeutic agent for diabetes according to claim 2, 3, 4, 5 or 6, wherein the inorganic acid is phosphoric acid, sulfuric acid or hydrochloric acid.
水非混和性有機溶媒からなる群から選ばれる少なくとも
一種類の抽出剤によって抽出処理して得た抽出物を有効
成分として含有する糖尿病治療剤。9. Diabetes containing, as an active ingredient, an extract obtained by subjecting earthworms to an extraction treatment with at least one extractant selected from the group consisting of aqueous solvents, water-miscible organic solvents and water-immiscible organic solvents. Therapeutic agent.
水、pH5〜10の緩衝液又はpH5〜10の調製水である特許請
求の範囲第9項記載の糖尿病治療剤。10. The therapeutic agent for diabetes according to claim 9, wherein the aqueous solvent is fresh water, distilled water, physiological saline, pH 5 to 10 buffer solution or pH 5 to 10 preparation water.
のアルコール類、ケトン類、エーテル類又はエステル類
である特許請求の範囲第9項記載の糖尿病治療剤。11. The water-miscible organic solvent has 1 to 4 carbon atoms.
10. The therapeutic agent for diabetes according to claim 9, which is the alcohol, ketone, ether or ester of the above.
10の炭化水素類、アルコール類、ケトン類、エステル類
又は炭素数1〜5のハロゲン化炭化水素である特許請求
の範囲第9項記載の糖尿病治療剤。12. The water-immiscible organic solvent has 6 to 6 carbon atoms.
The antidiabetic agent according to claim 9, which is 10 hydrocarbons, alcohols, ketones, esters or halogenated hydrocarbons having 1 to 5 carbon atoms.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62204905A JPH0780778B2 (en) | 1987-08-18 | 1987-08-18 | Antidiabetic agent |
| KR1019880007132A KR930002010B1 (en) | 1987-08-18 | 1988-06-14 | Antidiabetics |
| US07/228,672 US5024844A (en) | 1987-08-18 | 1988-08-05 | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient |
| DE3827623A DE3827623C2 (en) | 1987-08-18 | 1988-08-15 | Process for the preparation of pharmaceutically usable dried earthworm powder and its use as an antihyperlipemic, anti-diabetic, antihypertensive and antihypotonic preparation |
| GB8819523A GB2208602B (en) | 1987-08-18 | 1988-08-17 | Process for the production of dried earthworm powder and antihyperlipemic,anti-diabetic,antihypertensive and antihypotensive preparations containing dried ear |
| CA000575021A CA1322956C (en) | 1987-08-18 | 1988-08-17 | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient |
| CN88106168A CN1031653A (en) | 1987-08-18 | 1988-08-18 | Dry earthworm powder and contain the hyperlipidemia of dry earthworm powder as active component, anti-diabetic, the production method of the preparation of resisting hypertension and hypotension |
| US07/641,519 US5128148A (en) | 1987-08-18 | 1991-01-15 | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62204905A JPH0780778B2 (en) | 1987-08-18 | 1987-08-18 | Antidiabetic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6447718A JPS6447718A (en) | 1989-02-22 |
| JPH0780778B2 true JPH0780778B2 (en) | 1995-08-30 |
Family
ID=16498329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62204905A Expired - Lifetime JPH0780778B2 (en) | 1987-08-18 | 1987-08-18 | Antidiabetic agent |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH0780778B2 (en) |
| KR (1) | KR930002010B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180044659A (en) * | 2016-10-24 | 2018-05-03 | 안동대학교 산학협력단 | Composition containing Lumbricus rubellus extract reducing lipid accumulation as effective component |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100363197B1 (en) * | 2000-07-11 | 2002-12-05 | (주)이오바이오텍 | the extracting method of earthworm's body fluids using water contained activated oxygen |
| KR100557892B1 (en) * | 2002-03-29 | 2006-03-10 | 보은군 | Loess earthworm powder, quasi-medicine products using the same and manufacturing method thereof |
| JP4699974B2 (en) * | 2006-09-29 | 2011-06-15 | Well Stone 有限会社 | Method for producing earthworm dry powder |
| US8137701B2 (en) | 2008-03-21 | 2012-03-20 | Well Stone Co. | Method of producing a dry earthworm powder |
| DK2105139T3 (en) | 2008-03-26 | 2010-10-25 | Well Stone Co | Process for preparing a dry earthworm powder |
| JP4886017B2 (en) | 2009-10-13 | 2012-02-29 | Well Stone 有限会社 | Method for producing earthworm dry powder |
| JP4808822B1 (en) | 2011-04-11 | 2011-11-02 | Well Stone 有限会社 | Method for producing earthworm dry powder |
| JP6047609B2 (en) * | 2014-03-29 | 2016-12-21 | 国立大学法人 新潟大学 | Composition for inhibiting fatty liver and renal hypertrophy due to diabetes and method for producing the same |
| JP5901092B1 (en) * | 2015-08-26 | 2016-04-06 | ワキ製薬株式会社 | Method for producing human dipeptidyl peptidase IV inhibitor |
| CN109922814B (en) | 2017-03-21 | 2020-10-30 | 井石有限会社 | Method for preparing nose drops composition |
| US11147842B2 (en) | 2017-03-21 | 2021-10-19 | Well Stone Co. | Method for producing therapeutic agent for skin lesions, and therapeutic agent for skin lesions |
| JP6249581B1 (en) * | 2017-06-12 | 2017-12-20 | ワキ製薬株式会社 | Method for producing carbohydrase inhibitor |
| CN118405975A (en) * | 2023-10-13 | 2024-07-30 | 齐齐哈尔医学院 | 8,10-dihydroxy-7(12)-zeinene and preparation method and application thereof |
-
1987
- 1987-08-18 JP JP62204905A patent/JPH0780778B2/en not_active Expired - Lifetime
-
1988
- 1988-06-14 KR KR1019880007132A patent/KR930002010B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180044659A (en) * | 2016-10-24 | 2018-05-03 | 안동대학교 산학협력단 | Composition containing Lumbricus rubellus extract reducing lipid accumulation as effective component |
Also Published As
| Publication number | Publication date |
|---|---|
| KR890003395A (en) | 1989-04-14 |
| KR930002010B1 (en) | 1993-03-20 |
| JPS6447718A (en) | 1989-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5024844A (en) | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient | |
| JPH0780778B2 (en) | Antidiabetic agent | |
| JP3037355B2 (en) | Method for producing therapeutic agent for patients with thrombosis | |
| KR101549944B1 (en) | Composition for treating and preventing overavtive bladder and cystitis | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| JPH0788308B2 (en) | Method for manufacturing earthworm dry powder | |
| KR930002011B1 (en) | Antihypertensive and antihpotensive preparations | |
| JPH0780777B2 (en) | Antihyperlipidemic agent | |
| AU606038B2 (en) | Tissue growth regulation | |
| EA014070B1 (en) | Use of a herbal composition for the treatment of inflammatory disorders | |
| RU2138271C1 (en) | Immunocorrecting agent and method of immunocorrection | |
| EA007844B1 (en) | Use of fermented wheat germ extract as anti-inflammatory agent | |
| JPH02215726A (en) | Diabete remedy | |
| JPH02215723A (en) | Blood pressure regulating agent | |
| JPH02193929A (en) | Diabete remedy | |
| JPH02215724A (en) | Preparation of earthworm dried powder | |
| US5616325A (en) | Stimulator of vascular endothelial cells and use thereof | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| KR930001983B1 (en) | Manufacturing method of earthworm dry powder | |
| JPH02193927A (en) | Blood pressure-regulating agent | |
| KR102150114B1 (en) | Composition for preventing, improving or treating arthritis comprising extract of Ganoderma lucidum, extract of Carthamus tinctorius L. seeds or mixture thereof | |
| JPH02193928A (en) | Antihyperlipidemia drug | |
| JP2003104901A (en) | Health-oriented composition | |
| KR102925701B1 (en) | Dried cell secretome for osteoarthritis treatment | |
| FR2630008A1 (en) | Dried earthworm powder which is useful as a medicament and process for preparing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |